JP5451611B2 - 11β−ヒドロキシステロイドデヒドロゲナーゼ1のサイクリックインヒビター - Google Patents
11β−ヒドロキシステロイドデヒドロゲナーゼ1のサイクリックインヒビター Download PDFInfo
- Publication number
- JP5451611B2 JP5451611B2 JP2010518226A JP2010518226A JP5451611B2 JP 5451611 B2 JP5451611 B2 JP 5451611B2 JP 2010518226 A JP2010518226 A JP 2010518226A JP 2010518226 A JP2010518226 A JP 2010518226A JP 5451611 B2 JP5451611 B2 JP 5451611B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- alkoxy
- cycloalkyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003112 inhibitor Substances 0.000 title description 9
- 102100036506 11-beta-hydroxysteroid dehydrogenase 1 Human genes 0.000 title description 3
- 101710186107 11-beta-hydroxysteroid dehydrogenase 1 Proteins 0.000 title 1
- 125000004122 cyclic group Chemical group 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 claims description 729
- -1 CO 2 H Chemical group 0.000 claims description 597
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 240
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 236
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 216
- 125000003545 alkoxy group Chemical group 0.000 claims description 210
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 170
- 150000001875 compounds Chemical class 0.000 claims description 166
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 165
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 162
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 160
- 125000004043 oxo group Chemical group O=* 0.000 claims description 156
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 152
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 128
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 claims description 127
- 125000001072 heteroaryl group Chemical group 0.000 claims description 121
- 125000000217 alkyl group Chemical group 0.000 claims description 114
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 111
- 150000003839 salts Chemical class 0.000 claims description 107
- 239000011737 fluorine Substances 0.000 claims description 102
- 229910052731 fluorine Inorganic materials 0.000 claims description 102
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 101
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 100
- 125000005366 cycloalkylthio group Chemical group 0.000 claims description 91
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 88
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 79
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 79
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 78
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 78
- 239000000460 chlorine Substances 0.000 claims description 78
- 229910052801 chlorine Inorganic materials 0.000 claims description 78
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 73
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 70
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 69
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims description 68
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 68
- 150000001408 amides Chemical class 0.000 claims description 67
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 67
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 65
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 65
- 229910052794 bromium Inorganic materials 0.000 claims description 65
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 63
- 229910052736 halogen Inorganic materials 0.000 claims description 62
- 150000002367 halogens Chemical group 0.000 claims description 62
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 62
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims description 55
- 229910052757 nitrogen Chemical class 0.000 claims description 52
- 125000003118 aryl group Chemical group 0.000 claims description 49
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 claims description 47
- 125000000623 heterocyclic group Chemical group 0.000 claims description 47
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 claims description 46
- 125000005148 cycloalkylalkanesulfinyl group Chemical group 0.000 claims description 41
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 40
- 125000004414 alkyl thio group Chemical group 0.000 claims description 39
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 38
- 125000001188 haloalkyl group Chemical group 0.000 claims description 37
- 125000002947 alkylene group Chemical group 0.000 claims description 33
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 29
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 27
- 125000004076 pyridyl group Chemical group 0.000 claims description 26
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 25
- 125000001769 aryl amino group Chemical group 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 22
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 21
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 20
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 claims description 19
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 18
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 15
- 125000001544 thienyl group Chemical group 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 14
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims description 14
- 239000001301 oxygen Substances 0.000 claims description 14
- 125000004633 N-oxo-pyridyl group Chemical group 0.000 claims description 13
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 13
- 125000005529 alkyleneoxy group Chemical group 0.000 claims description 12
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 12
- 125000003386 piperidinyl group Chemical group 0.000 claims description 11
- 125000000335 thiazolyl group Chemical group 0.000 claims description 11
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000003368 amide group Chemical class 0.000 claims description 9
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 125000001153 fluoro group Chemical group F* 0.000 claims description 9
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 230000014509 gene expression Effects 0.000 claims description 8
- 125000006262 isopropyl amino sulfonyl group Chemical group 0.000 claims description 8
- 125000004193 piperazinyl group Chemical group 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 8
- 229920002554 vinyl polymer Polymers 0.000 claims description 8
- 125000006263 dimethyl aminosulfonyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])S(*)(=O)=O 0.000 claims description 7
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims description 2
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 13
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 83
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 82
- 125000001424 substituent group Chemical group 0.000 description 71
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 49
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 42
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 39
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 31
- 239000003862 glucocorticoid Substances 0.000 description 31
- 229910052739 hydrogen Inorganic materials 0.000 description 31
- 239000001257 hydrogen Substances 0.000 description 29
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 28
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 27
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 26
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 24
- 125000004433 nitrogen atom Chemical group N* 0.000 description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 21
- 125000003226 pyrazolyl group Chemical group 0.000 description 21
- 125000001207 fluorophenyl group Chemical group 0.000 description 19
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 18
- 229940037128 systemic glucocorticoids Drugs 0.000 description 18
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 17
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 17
- 125000005479 oxodihydropyridyl group Chemical group 0.000 description 17
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 16
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 15
- 229960000890 hydrocortisone Drugs 0.000 description 14
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 14
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 13
- 125000003373 pyrazinyl group Chemical group 0.000 description 13
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 150000001924 cycloalkanes Chemical class 0.000 description 12
- 150000004867 thiadiazoles Chemical group 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 11
- LOZWAPSEEHRYPG-UHFFFAOYSA-N 1,4-dithiane Chemical compound C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 10
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 10
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 10
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 9
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 8
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 125000005145 cycloalkylaminosulfonyl group Chemical group 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 7
- OTVAEFIXJLOWRX-UHFFFAOYSA-N 2,2-dichloro-n-[1,3-dihydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]acetamide Chemical group CS(=O)(=O)C1=CC=C(C(O)C(CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-UHFFFAOYSA-N 0.000 description 7
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 7
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 208000001145 Metabolic Syndrome Diseases 0.000 description 7
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 7
- 230000004410 intraocular pressure Effects 0.000 description 7
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 7
- 108010086356 11-beta-Hydroxysteroid Dehydrogenase Type 2 Proteins 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 6
- ADBZIZGMAVRJPN-UHFFFAOYSA-N 1,2,5-thiadiazolidine 1,1-dioxide Chemical compound O=S1(=O)NCCN1 ADBZIZGMAVRJPN-UHFFFAOYSA-N 0.000 description 5
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 5
- XGYCWCIGCYGQFU-UHFFFAOYSA-N 1,2-thiazolidine 1,1-dioxide Chemical compound O=S1(=O)CCCN1 XGYCWCIGCYGQFU-UHFFFAOYSA-N 0.000 description 5
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 5
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 5
- OYELEBBISJGNHJ-UHFFFAOYSA-N 1,3-oxazinan-2-one Chemical compound O=C1NCCCO1 OYELEBBISJGNHJ-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- GFPOCAYEKCWFPD-UHFFFAOYSA-N 1-(2,2,2-trifluoroethyl)piperazine Chemical compound FC(F)(F)CN1CCNCC1 GFPOCAYEKCWFPD-UHFFFAOYSA-N 0.000 description 5
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 description 5
- 102000006739 11-beta-Hydroxysteroid Dehydrogenase Type 2 Human genes 0.000 description 5
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 5
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 5
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 5
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 5
- IHXNIOYEXQWUNI-UHFFFAOYSA-N 4,5-dihydro-1h-pyrimidin-6-one Chemical compound O=C1CCN=CN1 IHXNIOYEXQWUNI-UHFFFAOYSA-N 0.000 description 5
- RRXSYZFVDIRTFB-UHFFFAOYSA-N C[CH]C1=CC=C(OC)C=C1 Chemical group C[CH]C1=CC=C(OC)C=C1 RRXSYZFVDIRTFB-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000277306 Esocidae Species 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 5
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 5
- 229950004696 flusalan Drugs 0.000 description 5
- 125000002883 imidazolyl group Chemical group 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 5
- VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 description 5
- 125000002757 morpholinyl group Chemical group 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 125000001715 oxadiazolyl group Chemical group 0.000 description 5
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 5
- 229960005141 piperazine Drugs 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 125000001113 thiadiazolyl group Chemical group 0.000 description 5
- KPROUAAIOYAJTP-AVRWGWEMSA-N (6r)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-(3-hydroxypropyl)-6-thiophen-2-yl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=CS1 KPROUAAIOYAJTP-AVRWGWEMSA-N 0.000 description 4
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 4
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 4
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 4
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 4
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 4
- ULHHBRRJSIKVCR-PJLCYBKHSA-N 3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(2,3-dihydroxypropyl)-6-propan-2-yl-1,3-oxazinan-2-one Chemical compound O=C1OC(C(C)C)(CC(O)CO)CCN1[C@@H](C)C1=CC=C(C=2C(=CC(F)=CC=2)F)C=C1 ULHHBRRJSIKVCR-PJLCYBKHSA-N 0.000 description 4
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 4
- 208000004611 Abdominal Obesity Diseases 0.000 description 4
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 4
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 4
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 4
- 102100021316 Mineralocorticoid receptor Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 4
- 229960004544 cortisone Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000005347 halocycloalkyl group Chemical group 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- YNTOKMNHRPSGFU-UHFFFAOYSA-N n-Propyl carbamate Chemical compound CCCOC(N)=O YNTOKMNHRPSGFU-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- GRECFJMRKUEXPU-HSZRJFAPSA-N (6r)-3-[3-(4-fluorophenyl)phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(C)C=2C=CC=CC=2)CN1C(C=1)=CC=CC=1C1=CC=C(F)C=C1 GRECFJMRKUEXPU-HSZRJFAPSA-N 0.000 description 3
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 3
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 3
- NQPJDJVGBDHCAD-UHFFFAOYSA-N 1,3-diazinan-2-one Chemical compound OC1=NCCCN1 NQPJDJVGBDHCAD-UHFFFAOYSA-N 0.000 description 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 3
- ZZNUHDXNMHQWAV-UHFFFAOYSA-N 3-[6-(2,4-difluorophenyl)pyridin-2-yl]-6-(2-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound O=C1OC(CCO)(C=2C(=CC=CC=2)F)CCN1C(N=1)=CC=CC=1C1=CC=C(F)C=C1F ZZNUHDXNMHQWAV-UHFFFAOYSA-N 0.000 description 3
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- DQYAEFFEMXBSCO-OOJLDXBWSA-N 6-ethenyl-6-(4-fluorophenyl)-3-[(1s)-1-phenylethyl]-1,3-oxazinan-2-one Chemical compound O1C(=O)N([C@@H](C)C=2C=CC=CC=2)CCC1(C=C)C1=CC=C(F)C=C1 DQYAEFFEMXBSCO-OOJLDXBWSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000014311 Cushing syndrome Diseases 0.000 description 3
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 3
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 3
- 208000002705 Glucose Intolerance Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 241001024304 Mino Species 0.000 description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- BGGQCYYULFFRLC-UHFFFAOYSA-N ethyl sulfamate Chemical compound CCOS(N)(=O)=O BGGQCYYULFFRLC-UHFFFAOYSA-N 0.000 description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- SXAUUPNZZAAJOG-YCRPNKLZSA-N (6r)-3-[(1s)-1-(4-bromophenyl)ethyl]-6-(4-fluorophenyl)-6-prop-2-enyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CC=C)CCN(C(O2)=O)[C@@H](C)C=2C=CC(Br)=CC=2)=CC=C(F)C=C1 SXAUUPNZZAAJOG-YCRPNKLZSA-N 0.000 description 2
- QSELYASLZRRGGG-BXKMTCNYSA-N (6r)-3-[(1s)-1-(4-cyclopropylphenyl)ethyl]-6-(4-fluorophenyl)-6-prop-2-enyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CC=C)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C2CC2)=CC=C(F)C=C1 QSELYASLZRRGGG-BXKMTCNYSA-N 0.000 description 2
- SLSMHOGJKAPYQU-MRDQGFSESA-N (6r)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C1([C@]2(CCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=C(F)C=C1 SLSMHOGJKAPYQU-MRDQGFSESA-N 0.000 description 2
- FDVFZPJZYBDRRS-HRAATJIYSA-N (6r)-3-[(1s)-1-cyclohexylethyl]-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-1,3-oxazinan-2-one Chemical compound C1([C@H](C)N2C(O[C@](CCCO)(CC2)C=2C=CC(F)=CC=2)=O)CCCCC1 FDVFZPJZYBDRRS-HRAATJIYSA-N 0.000 description 2
- BRCSKQYCZLOWED-XMMPIXPASA-N (6r)-3-[3-(2,4-difluorophenyl)phenyl]-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@@](OC1=O)(CCO)C=2C=CC=CC=2)CN1C(C=1)=CC=CC=1C1=CC=C(F)C=C1F BRCSKQYCZLOWED-XMMPIXPASA-N 0.000 description 2
- ZZNUHDXNMHQWAV-HSZRJFAPSA-N (6r)-3-[6-(2,4-difluorophenyl)pyridin-2-yl]-6-(2-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C([C@@](OC1=O)(CCO)C=2C(=CC=CC=2)F)CN1C(N=1)=CC=CC=1C1=CC=C(F)C=C1F ZZNUHDXNMHQWAV-HSZRJFAPSA-N 0.000 description 2
- IXGMDVQFYQFYDF-RXFWQSSRSA-N (6r)-6-(3-hydroxypropyl)-6-phenyl-3-[(1s)-1-(4-pyridin-3-ylphenyl)ethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=NC=CC=2)=CC=CC=C1 IXGMDVQFYQFYDF-RXFWQSSRSA-N 0.000 description 2
- XKUYBHWZCQUCGO-HFJWLAOPSA-N (6r)-6-(4-fluorophenyl)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C1([C@]2(CCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=C(F)C=C1 XKUYBHWZCQUCGO-HFJWLAOPSA-N 0.000 description 2
- XRTFMNIRZNJJHD-OXJNMPFZSA-N (6r)-6-methyl-6-(2-methylphenyl)-3-[(1s)-1-phenylethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(C)CCN(C(O2)=O)[C@@H](C)C=2C=CC=CC=2)=CC=CC=C1C XRTFMNIRZNJJHD-OXJNMPFZSA-N 0.000 description 2
- QIMFMKBZKNFZQM-OXJNMPFZSA-N (6r)-6-methyl-6-(3-methylphenyl)-3-[(1s)-1-phenylethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(C)CCN(C(O2)=O)[C@@H](C)C=2C=CC=CC=2)=CC=CC(C)=C1 QIMFMKBZKNFZQM-OXJNMPFZSA-N 0.000 description 2
- VQYBDAASFBMKEP-OXJNMPFZSA-N (6r)-6-methyl-6-(4-methylphenyl)-3-[(1s)-1-phenylethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(C)CCN(C(O2)=O)[C@@H](C)C=2C=CC=CC=2)=CC=C(C)C=C1 VQYBDAASFBMKEP-OXJNMPFZSA-N 0.000 description 2
- UXYULVUOOAOBIA-ZKYUUJBMSA-N (6s)-3-[(1s)-1-(4-bromophenyl)ethyl]-6-[(2r)-2,3-dihydroxypropyl]-6-(4-fluorophenyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(C[C@@H](O)CO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(Br)=CC=2)=CC=C(F)C=C1 UXYULVUOOAOBIA-ZKYUUJBMSA-N 0.000 description 2
- UXYULVUOOAOBIA-JBYOLUDKSA-N (6s)-3-[(1s)-1-(4-bromophenyl)ethyl]-6-[(2s)-2,3-dihydroxypropyl]-6-(4-fluorophenyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(C[C@H](O)CO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(Br)=CC=2)=CC=C(F)C=C1 UXYULVUOOAOBIA-JBYOLUDKSA-N 0.000 description 2
- JQRPZOWAALFXBW-FPOVZHCZSA-N (6s)-3-[(1s)-1-(4-bromophenyl)propyl]-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCO)CCN(C(O2)=O)[C@@H](CC)C=2C=CC(Br)=CC=2)=CC=C(F)C=C1 JQRPZOWAALFXBW-FPOVZHCZSA-N 0.000 description 2
- JYUZCHJMXCOJJR-MRDQGFSESA-N (6s)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-2-oxo-6-[2-(sulfamoylamino)ethyl]-1,3-oxazinane Chemical compound C1([C@@]2(CCNS(N)(=O)=O)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=C(F)C=C1 JYUZCHJMXCOJJR-MRDQGFSESA-N 0.000 description 2
- ZTMCZWXIGPCMLA-JMQGSBJISA-N (6s)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CC(C)(C)O)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=C(F)C=C1 ZTMCZWXIGPCMLA-JMQGSBJISA-N 0.000 description 2
- SLSMHOGJKAPYQU-QLXKLKPCSA-N (6s)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=C(F)C=C1 SLSMHOGJKAPYQU-QLXKLKPCSA-N 0.000 description 2
- FKSSIYWQQLRDKP-MYUZEXMDSA-N (6s)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-6-(2-methoxyethyl)-1,3-oxazinan-2-one Chemical compound C1=CC([C@H](C)N2CC[C@](OC2=O)(CCOC)C=2C=CC(F)=CC=2)=CC=C1C1=CC=C(F)C=C1F FKSSIYWQQLRDKP-MYUZEXMDSA-N 0.000 description 2
- NDJIIYAAWZLVPP-MYUZEXMDSA-N (6s)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-6-(2-oxopropyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CC(C)=O)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=C(F)C=C1 NDJIIYAAWZLVPP-MYUZEXMDSA-N 0.000 description 2
- BRCSKQYCZLOWED-DEOSSOPVSA-N (6s)-3-[3-(2,4-difluorophenyl)phenyl]-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(CCO)C=2C=CC=CC=2)CN1C(C=1)=CC=CC=1C1=CC=C(F)C=C1F BRCSKQYCZLOWED-DEOSSOPVSA-N 0.000 description 2
- GRECFJMRKUEXPU-QHCPKHFHSA-N (6s)-3-[3-(4-fluorophenyl)phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@@](OC1=O)(C)C=2C=CC=CC=2)CN1C(C=1)=CC=CC=1C1=CC=C(F)C=C1 GRECFJMRKUEXPU-QHCPKHFHSA-N 0.000 description 2
- ZZNUHDXNMHQWAV-QHCPKHFHSA-N (6s)-3-[6-(2,4-difluorophenyl)pyridin-2-yl]-6-(2-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(CCO)C=2C(=CC=CC=2)F)CN1C(N=1)=CC=CC=1C1=CC=C(F)C=C1F ZZNUHDXNMHQWAV-QHCPKHFHSA-N 0.000 description 2
- ZJBOOJMHWPFBRE-QHCPKHFHSA-N (6s)-6-(2-fluorophenyl)-3-[6-(4-fluorophenyl)pyridin-2-yl]-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(CCO)C=2C(=CC=CC=2)F)CN1C(N=1)=CC=CC=1C1=CC=C(F)C=C1 ZJBOOJMHWPFBRE-QHCPKHFHSA-N 0.000 description 2
- XKUYBHWZCQUCGO-QYBDOPJKSA-N (6s)-6-(4-fluorophenyl)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=C(F)C=C1 XKUYBHWZCQUCGO-QYBDOPJKSA-N 0.000 description 2
- FNTHZWPWNKYVAW-YWZLYKJASA-N (6s)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-3-[(1s)-1-phenylethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC=CC=2)=CC=C(F)C=C1 FNTHZWPWNKYVAW-YWZLYKJASA-N 0.000 description 2
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- FKKJWWOASDLEKD-UHFFFAOYSA-N 2-[3-(6-methyl-2-oxo-6-phenyl-1,3-oxazinan-3-yl)phenyl]benzonitrile Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=CC=C1C#N FKKJWWOASDLEKD-UHFFFAOYSA-N 0.000 description 2
- PNIHGQHDPPRIPD-UHFFFAOYSA-N 3-(2-chlorophenyl)-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C1=CC=CC=C1Cl PNIHGQHDPPRIPD-UHFFFAOYSA-N 0.000 description 2
- QZMQRSGOWWSPRH-UHFFFAOYSA-N 3-(3-bromophenyl)-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(CCO)(C=2C=CC=CC=2)CCN1C1=CC=CC(Br)=C1 QZMQRSGOWWSPRH-UHFFFAOYSA-N 0.000 description 2
- FCQMFQGLDUEZDD-UHFFFAOYSA-N 3-(3-bromophenyl)-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C1=CC=CC(Br)=C1 FCQMFQGLDUEZDD-UHFFFAOYSA-N 0.000 description 2
- CERIMNKGQLUDEA-DBWCEAHUSA-N 3-[(1s)-1-(4-bromophenyl)ethyl]-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-4-methyl-1,3-oxazinan-2-one Chemical compound O1C(=O)N([C@@H](C)C=2C=CC(Br)=CC=2)C(C)CC1(CCO)C1=CC=C(F)C=C1 CERIMNKGQLUDEA-DBWCEAHUSA-N 0.000 description 2
- CXZBFXPOCBHESM-KEJDIYNNSA-N 3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(3-hydroxypropyl)-6-propan-2-yl-1,3-oxazinan-2-one Chemical compound O=C1OC(C(C)C)(CCCO)CCN1[C@@H](C)C1=CC=C(C=2C(=CC(F)=CC=2)F)C=C1 CXZBFXPOCBHESM-KEJDIYNNSA-N 0.000 description 2
- LSPGCFCDJOHGNZ-UHFFFAOYSA-N 3-[(2-bromophenyl)methyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1CC1=CC=CC=C1Br LSPGCFCDJOHGNZ-UHFFFAOYSA-N 0.000 description 2
- CERIMNKGQLUDEA-UHFFFAOYSA-N 3-[1-(4-bromophenyl)ethyl]-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-4-methyl-1,3-oxazinan-2-one Chemical compound C=1C=C(Br)C=CC=1C(C)N(C(O1)=O)C(C)CC1(CCO)C1=CC=C(F)C=C1 CERIMNKGQLUDEA-UHFFFAOYSA-N 0.000 description 2
- ULHHBRRJSIKVCR-UHFFFAOYSA-N 3-[1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(2,3-dihydroxypropyl)-6-propan-2-yl-1,3-oxazinan-2-one Chemical compound O=C1OC(C(C)C)(CC(O)CO)CCN1C(C)C1=CC=C(C=2C(=CC(F)=CC=2)F)C=C1 ULHHBRRJSIKVCR-UHFFFAOYSA-N 0.000 description 2
- IEQHZGFXUXYXTQ-UHFFFAOYSA-N 3-[3-(2,4-difluorophenyl)-4-fluorophenyl]-6-(2-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound O=C1OC(CCO)(C=2C(=CC=CC=2)F)CCN1C(C=1)=CC=C(F)C=1C1=CC=C(F)C=C1F IEQHZGFXUXYXTQ-UHFFFAOYSA-N 0.000 description 2
- URQVFDCWQACMSU-UHFFFAOYSA-N 3-[3-(2,4-difluorophenyl)-4-fluorophenyl]-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound O=C1OC(CCO)(C=2C=CC(F)=CC=2)CCN1C(C=1)=CC=C(F)C=1C1=CC=C(F)C=C1F URQVFDCWQACMSU-UHFFFAOYSA-N 0.000 description 2
- BRCSKQYCZLOWED-UHFFFAOYSA-N 3-[3-(2,4-difluorophenyl)phenyl]-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(CCO)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=C(F)C=C1F BRCSKQYCZLOWED-UHFFFAOYSA-N 0.000 description 2
- TYQJYQYIJIVXSP-UHFFFAOYSA-N 3-[3-(2,4-difluorophenyl)phenyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(CCCO)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=C(F)C=C1F TYQJYQYIJIVXSP-UHFFFAOYSA-N 0.000 description 2
- HLIYQMYOMGNOFM-UHFFFAOYSA-N 3-[3-(2,4-difluorophenyl)phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=C(F)C=C1F HLIYQMYOMGNOFM-UHFFFAOYSA-N 0.000 description 2
- QOHJATQGUIFXMI-UHFFFAOYSA-N 3-[3-(2,4-difluorophenyl)phenyl]-6-methyl-6-pyridin-2-yl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2N=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=C(F)C=C1F QOHJATQGUIFXMI-UHFFFAOYSA-N 0.000 description 2
- NAJQWCLNVIYERJ-UHFFFAOYSA-N 3-[3-(2,4-difluorophenyl)phenyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one Chemical compound FC1=CC(F)=CC=C1C1=CC=CC(N2C(OC(CC=C)(CC2)C=2C=CC=CC=2)=O)=C1 NAJQWCLNVIYERJ-UHFFFAOYSA-N 0.000 description 2
- HRIFFFQIHSNZCB-UHFFFAOYSA-N 3-[3-(2,5-difluorophenyl)phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC(F)=CC=C1F HRIFFFQIHSNZCB-UHFFFAOYSA-N 0.000 description 2
- LFKAYPNCNLKVMW-UHFFFAOYSA-N 3-[3-(2,6-dichlorophenyl)phenyl]-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(CCO)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=C(Cl)C=CC=C1Cl LFKAYPNCNLKVMW-UHFFFAOYSA-N 0.000 description 2
- DNISDJNHMIIZEI-UHFFFAOYSA-N 3-[3-(2,6-dichlorophenyl)phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=C(Cl)C=CC=C1Cl DNISDJNHMIIZEI-UHFFFAOYSA-N 0.000 description 2
- MYYYYXMOOBKOJL-UHFFFAOYSA-N 3-[3-(3,5-difluorophenyl)phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC(F)=CC(F)=C1 MYYYYXMOOBKOJL-UHFFFAOYSA-N 0.000 description 2
- OGLNYJGPAHIVTG-UHFFFAOYSA-N 3-[4-fluoro-3-(4-fluorophenyl)phenyl]-6-(2-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound O=C1OC(CCO)(C=2C(=CC=CC=2)F)CCN1C(C=1)=CC=C(F)C=1C1=CC=C(F)C=C1 OGLNYJGPAHIVTG-UHFFFAOYSA-N 0.000 description 2
- IIAKMAWFDUBOEW-UHFFFAOYSA-N 3-[4-fluoro-3-(4-fluorophenyl)phenyl]-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(CCO)(C=2C=CC=CC=2)CCN1C(C=1)=CC=C(F)C=1C1=CC=C(F)C=C1 IIAKMAWFDUBOEW-UHFFFAOYSA-N 0.000 description 2
- WVIKTKCFEJYSSM-UHFFFAOYSA-N 3-[4-fluoro-3-(4-fluorophenyl)phenyl]-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound O=C1OC(CCO)(C=2C=CC(F)=CC=2)CCN1C(C=1)=CC=C(F)C=1C1=CC=C(F)C=C1 WVIKTKCFEJYSSM-UHFFFAOYSA-N 0.000 description 2
- WZELCWHHNLQSLR-UHFFFAOYSA-N 3-[5-chloro-6-(2,4-difluorophenyl)pyridin-2-yl]-6-(2-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound O=C1OC(CCO)(C=2C(=CC=CC=2)F)CCN1C(N=1)=CC=C(Cl)C=1C1=CC=C(F)C=C1F WZELCWHHNLQSLR-UHFFFAOYSA-N 0.000 description 2
- OFIMPNOQMXPORL-UHFFFAOYSA-N 3-[6-(2,4-difluorophenyl)pyridin-2-yl]-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound O=C1OC(CCO)(C=2C=CC(F)=CC=2)CCN1C(N=1)=CC=CC=1C1=CC=C(F)C=C1F OFIMPNOQMXPORL-UHFFFAOYSA-N 0.000 description 2
- 125000000981 3-amino-3-oxopropyl group Chemical group [H]C([*])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 2
- IYZIARNSXPGYSC-UHFFFAOYSA-N 3-phenylbenzamide Chemical compound NC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1 IYZIARNSXPGYSC-UHFFFAOYSA-N 0.000 description 2
- YRLSCCZSKWRLSP-UHFFFAOYSA-N 3-phenylbenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(C=2C=CC=CC=2)=C1 YRLSCCZSKWRLSP-UHFFFAOYSA-N 0.000 description 2
- JVFCCRJSBNUDDU-UHFFFAOYSA-N 4-phenylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=CC=CC=C1 JVFCCRJSBNUDDU-UHFFFAOYSA-N 0.000 description 2
- XKLWFNZCTAICAO-UHFFFAOYSA-N 6-(2-aminoethyl)-3-[3-(2,4-difluorophenyl)phenyl]-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(CCN)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=C(F)C=C1F XKLWFNZCTAICAO-UHFFFAOYSA-N 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- YPCOLEPFZYAVIO-UHFFFAOYSA-N 6-methyl-3-(3-methylphenyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound CC1=CC=CC(N2C(OC(C)(CC2)C=2C=CC=CC=2)=O)=C1 YPCOLEPFZYAVIO-UHFFFAOYSA-N 0.000 description 2
- IOENRSKDLFZWGE-UHFFFAOYSA-N 6-methyl-3-(3-phenoxyphenyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1OC1=CC=CC=C1 IOENRSKDLFZWGE-UHFFFAOYSA-N 0.000 description 2
- PMNFSAGLIMRJAD-UHFFFAOYSA-N 6-methyl-6-phenyl-3-(3-phenylphenyl)-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=CC=C1 PMNFSAGLIMRJAD-UHFFFAOYSA-N 0.000 description 2
- DSWZMJKPAYWMJP-UHFFFAOYSA-N 6-methyl-6-phenyl-3-(3-thiophen-2-ylphenyl)-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=CS1 DSWZMJKPAYWMJP-UHFFFAOYSA-N 0.000 description 2
- LVYAAPIPLDIUSX-FUKCDUGKSA-N 6-methyl-6-phenyl-3-[(1s)-1-phenylethyl]-1,3-oxazinan-2-one Chemical compound O1C(=O)N([C@@H](C)C=2C=CC=CC=2)CCC1(C)C1=CC=CC=C1 LVYAAPIPLDIUSX-FUKCDUGKSA-N 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 108700043439 Cortisone reductase deficiency Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 241000239366 Euphausiacea Species 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 201000004076 cortisone reductase deficiency Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- ZJXZSIYSNXKHEA-UHFFFAOYSA-N ethyl dihydrogen phosphate Chemical compound CCOP(O)(O)=O ZJXZSIYSNXKHEA-UHFFFAOYSA-N 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 108010002929 galactose-6-phosphate dehydrogenase Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 201000010066 hyperandrogenism Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- VGTVYPMTXNOUAZ-QMHKHESXSA-N methyl 4-[(1s)-1-[(6r)-6-(4-fluorophenyl)-2-oxo-6-prop-2-enyl-1,3-oxazinan-3-yl]ethyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1[C@H](C)N1C(=O)O[C@@](CC=C)(C=2C=CC(F)=CC=2)CC1 VGTVYPMTXNOUAZ-QMHKHESXSA-N 0.000 description 2
- SURZCVYFPAXNGN-UHFFFAOYSA-N methyl-carbamic acid ethyl ester Chemical compound CCOC(=O)NC SURZCVYFPAXNGN-UHFFFAOYSA-N 0.000 description 2
- 239000002395 mineralocorticoid Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- ABZQVQCOZWJEOI-UHFFFAOYSA-N n-[2-[3-[3-(2,4-difluorophenyl)phenyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]ethyl]acetamide Chemical compound O=C1OC(CCNC(=O)C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=C(F)C=C1F ABZQVQCOZWJEOI-UHFFFAOYSA-N 0.000 description 2
- YSYWZSPOHHSHAR-UHFFFAOYSA-N n-[2-[3-[3-(2,4-difluorophenyl)phenyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]ethyl]methanesulfonamide Chemical compound O=C1OC(CCNS(=O)(=O)C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=C(F)C=C1F YSYWZSPOHHSHAR-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- DNGMYXZLJGHHOM-UHFFFAOYSA-N thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCCCN1 DNGMYXZLJGHHOM-UHFFFAOYSA-N 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- XXRWLMZMYFVDIH-HRAATJIYSA-N (6R)-6-(2-hydroxyethyl)-3-[(1S)-1-(4-methoxyphenyl)ethyl]-6-phenyl-1,3-oxazinan-2-one Chemical compound C1=CC(OC)=CC=C1[C@H](C)N1C(=O)O[C@](CCO)(C=2C=CC=CC=2)CC1 XXRWLMZMYFVDIH-HRAATJIYSA-N 0.000 description 1
- PNIHGQHDPPRIPD-QGZVFWFLSA-N (6r)-3-(2-chlorophenyl)-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(C)C=2C=CC=CC=2)CN1C1=CC=CC=C1Cl PNIHGQHDPPRIPD-QGZVFWFLSA-N 0.000 description 1
- FCQMFQGLDUEZDD-QGZVFWFLSA-N (6r)-3-(3-bromophenyl)-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(C)C=2C=CC=CC=2)CN1C1=CC=CC(Br)=C1 FCQMFQGLDUEZDD-QGZVFWFLSA-N 0.000 description 1
- SLSMHOGJKAPYQU-WGDIFIGCSA-N (6r)-3-[(1r)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C1([C@]2(CCO)CCN(C(O2)=O)[C@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=C(F)C=C1 SLSMHOGJKAPYQU-WGDIFIGCSA-N 0.000 description 1
- GHMGZYVCMBQHQS-IFXJQAMLSA-N (6r)-3-[(1s)-1-(4-bromophenyl)ethyl]-6-prop-2-enyl-6-thiophen-2-yl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CC=C)CCN(C(O2)=O)[C@@H](C)C=2C=CC(Br)=CC=2)=CC=CS1 GHMGZYVCMBQHQS-IFXJQAMLSA-N 0.000 description 1
- MJISMVNNZLUKIQ-QMHKHESXSA-N (6r)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(2-hydroxyethyl)-6-propan-2-yl-1,3-oxazinan-2-one Chemical compound O=C1O[C@@](C(C)C)(CCO)CCN1[C@@H](C)C1=CC=C(C=2C(=CC(F)=CC=2)F)C=C1 MJISMVNNZLUKIQ-QMHKHESXSA-N 0.000 description 1
- PUCNQCMCYLVVQG-UPCLLVRISA-N (6r)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(2-hydroxyethyl)-6-thiophen-2-yl-1,3-oxazinan-2-one Chemical compound C1([C@]2(CCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=CS1 PUCNQCMCYLVVQG-UPCLLVRISA-N 0.000 description 1
- OFTIABJUDZBFSR-AFJIDDCJSA-N (6r)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(3-hydroxy-3-methylbutyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCC(C)(C)O)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=CC=C1 OFTIABJUDZBFSR-AFJIDDCJSA-N 0.000 description 1
- PDBVUENMKQBWQZ-UZTOHYMASA-N (6r)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=CC=C1 PDBVUENMKQBWQZ-UZTOHYMASA-N 0.000 description 1
- USMSKUDZCFKKOS-URAOTHONSA-N (6r)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-6-(2-morpholin-4-ylethyl)-1,3-oxazinan-2-one Chemical compound C([C@@]1(CCN(C(O1)=O)[C@@H](C)C=1C=CC(=CC=1)C=1C(=CC(F)=CC=1)F)C=1C=CC(F)=CC=1)CN1CCOCC1 USMSKUDZCFKKOS-URAOTHONSA-N 0.000 description 1
- PBFRLXOIGZCFAL-HMILPKGGSA-N (6r)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-6-[2-(2-hydroxyethylamino)ethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCNCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=C(F)C=C1 PBFRLXOIGZCFAL-HMILPKGGSA-N 0.000 description 1
- HMGUNNURUKBIDA-CBZJRKILSA-N (6r)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-6-[2-(2h-tetrazol-5-yl)ethyl]-1,3-oxazinan-2-one Chemical compound C([C@@]1(CCN(C(O1)=O)[C@@H](C)C=1C=CC(=CC=1)C=1C(=CC(F)=CC=1)F)C=1C=CC(F)=CC=1)CC1=NN=NN1 HMGUNNURUKBIDA-CBZJRKILSA-N 0.000 description 1
- SQVJMTXJTUXMRN-UZTOHYMASA-N (6r)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-phenyl-6-propyl-1,3-oxazinan-2-one Chemical compound C1=CC([C@H](C)N2CC[C@](OC2=O)(CCC)C=2C=CC=CC=2)=CC=C1C1=CC=C(F)C=C1F SQVJMTXJTUXMRN-UZTOHYMASA-N 0.000 description 1
- ZZGVWZOGQQLPBH-XTEPFMGCSA-N (6r)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]propyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](CC)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=CC=C1 ZZGVWZOGQQLPBH-XTEPFMGCSA-N 0.000 description 1
- AOHUCFUOVXHCLK-UQBPGWFLSA-N (6r)-3-[(1s)-1-[4-(2-hydroxy-2-methylpropyl)phenyl]ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(CC(C)(C)O)=CC=2)=CC=CC=C1 AOHUCFUOVXHCLK-UQBPGWFLSA-N 0.000 description 1
- PDIARYFKTRBTNB-BXKMTCNYSA-N (6r)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-(2-hydroxyethyl)-6-thiophen-2-yl-1,3-oxazinan-2-one Chemical compound C1([C@]2(CCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=CS1 PDIARYFKTRBTNB-BXKMTCNYSA-N 0.000 description 1
- CJTIHIUCNPYRRL-KCWXNJEJSA-N (6r)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-(3-hydroxy-3-methylbutyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCC(C)(C)O)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=CC=C1 CJTIHIUCNPYRRL-KCWXNJEJSA-N 0.000 description 1
- NRQVLVGDMUNLPF-CCLHPLFOSA-N (6r)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=CC=C1 NRQVLVGDMUNLPF-CCLHPLFOSA-N 0.000 description 1
- GJUUUICEUNCMCS-AVRWGWEMSA-N (6r)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-prop-2-enyl-6-thiophen-2-yl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CC=C)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=CS1 GJUUUICEUNCMCS-AVRWGWEMSA-N 0.000 description 1
- ZASJMILIAPSNCZ-XTEPFMGCSA-N (6r)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]propyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](CC)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=CC=C1 ZASJMILIAPSNCZ-XTEPFMGCSA-N 0.000 description 1
- JVTMFWXKBGTYDB-HFJWLAOPSA-N (6r)-3-[(1s)-1-[4-(5-chloropyridin-3-yl)phenyl]ethyl]-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=C(Cl)C=NC=2)=CC=C(F)C=C1 JVTMFWXKBGTYDB-HFJWLAOPSA-N 0.000 description 1
- QAJYZVCUZHBDBT-AFMDSPMNSA-N (6r)-3-[(1s)-1-[4-(5-fluoropyridin-3-yl)phenyl]ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=C(F)C=NC=2)=CC=CC=C1 QAJYZVCUZHBDBT-AFMDSPMNSA-N 0.000 description 1
- NYBSHWQXEOLRKC-OYHNWAKOSA-N (6r)-3-[(1s)-1-[4-(difluoromethoxy)phenyl]ethyl]-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(OC(F)F)=CC=2)=CC=C(F)C=C1 NYBSHWQXEOLRKC-OYHNWAKOSA-N 0.000 description 1
- HTHSEXCVPBIVRV-OYHNWAKOSA-N (6r)-3-[(1s)-1-[4-(difluoromethoxy)phenyl]ethyl]-6-(4-fluorophenyl)-6-prop-2-enyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CC=C)CCN(C(O2)=O)[C@@H](C)C=2C=CC(OC(F)F)=CC=2)=CC=C(F)C=C1 HTHSEXCVPBIVRV-OYHNWAKOSA-N 0.000 description 1
- BHVSKPTZJSEDJR-HTAPYJJXSA-N (6r)-3-[(1s)-1-[4-(hydroxymethyl)phenyl]ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(CO)=CC=2)=CC=CC=C1 BHVSKPTZJSEDJR-HTAPYJJXSA-N 0.000 description 1
- LSPGCFCDJOHGNZ-GOSISDBHSA-N (6r)-3-[(2-bromophenyl)methyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(C)C=2C=CC=CC=2)CN1CC1=CC=CC=C1Br LSPGCFCDJOHGNZ-GOSISDBHSA-N 0.000 description 1
- GHNKKJSPGBEQKD-HSZRJFAPSA-N (6r)-3-[3-(2-chlorophenyl)phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(C)C=2C=CC=CC=2)CN1C(C=1)=CC=CC=1C1=CC=CC=C1Cl GHNKKJSPGBEQKD-HSZRJFAPSA-N 0.000 description 1
- CJOYNVRXISNTHV-HSZRJFAPSA-N (6r)-3-[3-(2-fluorophenyl)phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(C)C=2C=CC=CC=2)CN1C(C=1)=CC=CC=1C1=CC=CC=C1F CJOYNVRXISNTHV-HSZRJFAPSA-N 0.000 description 1
- VZFDJCRSLBVOGH-XMMPIXPASA-N (6r)-3-[3-(2-methoxyphenyl)phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound COC1=CC=CC=C1C1=CC=CC(N2C(O[C@](C)(CC2)C=2C=CC=CC=2)=O)=C1 VZFDJCRSLBVOGH-XMMPIXPASA-N 0.000 description 1
- RLNXULRKOMDPDW-HSZRJFAPSA-N (6r)-3-[3-(3-chlorophenyl)phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(C)C=2C=CC=CC=2)CN1C(C=1)=CC=CC=1C1=CC=CC(Cl)=C1 RLNXULRKOMDPDW-HSZRJFAPSA-N 0.000 description 1
- SFOFGISPBWRXTM-HSZRJFAPSA-N (6r)-3-[3-(3-fluorophenyl)phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(C)C=2C=CC=CC=2)CN1C(C=1)=CC=CC=1C1=CC=CC(F)=C1 SFOFGISPBWRXTM-HSZRJFAPSA-N 0.000 description 1
- FMFCPPMAYOGHKS-XMMPIXPASA-N (6r)-3-[3-(3-methoxyphenyl)phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound COC1=CC=CC(C=2C=C(C=CC=2)N2C(O[C@](C)(CC2)C=2C=CC=CC=2)=O)=C1 FMFCPPMAYOGHKS-XMMPIXPASA-N 0.000 description 1
- DGRZIUAMDOMXOF-HSZRJFAPSA-N (6r)-3-[3-(4-hydroxyphenyl)phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(C)C=2C=CC=CC=2)CN1C(C=1)=CC=CC=1C1=CC=C(O)C=C1 DGRZIUAMDOMXOF-HSZRJFAPSA-N 0.000 description 1
- XYMFJLWCTXMXHU-UZTOHYMASA-N (6r)-6-(2-fluorophenyl)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-(3-hydroxypropyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=CC=C1F XYMFJLWCTXMXHU-UZTOHYMASA-N 0.000 description 1
- OUTJYNQORJHZGJ-HSZRJFAPSA-N (6r)-6-(2-fluorophenyl)-3-[6-(4-fluorophenyl)-1-oxidopyridin-1-ium-2-yl]-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical class C([C@@](OC1=O)(CCO)C=2C(=CC=CC=2)F)CN1C([N+]=1[O-])=CC=CC=1C1=CC=C(F)C=C1 OUTJYNQORJHZGJ-HSZRJFAPSA-N 0.000 description 1
- ZJBOOJMHWPFBRE-HSZRJFAPSA-N (6r)-6-(2-fluorophenyl)-3-[6-(4-fluorophenyl)pyridin-2-yl]-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C([C@@](OC1=O)(CCO)C=2C(=CC=CC=2)F)CN1C(N=1)=CC=CC=1C1=CC=C(F)C=C1 ZJBOOJMHWPFBRE-HSZRJFAPSA-N 0.000 description 1
- CMLGYKTUOFEFSU-XRHLQHRESA-N (6r)-6-(3-aminopropyl)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCN)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=C(F)C=C1 CMLGYKTUOFEFSU-XRHLQHRESA-N 0.000 description 1
- KGJLDEILXUOVAN-HSZRJFAPSA-N (6r)-6-(3-chlorophenyl)-6-methyl-3-(3-phenylphenyl)-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(C)C=2C=C(Cl)C=CC=2)CN1C(C=1)=CC=CC=1C1=CC=CC=C1 KGJLDEILXUOVAN-HSZRJFAPSA-N 0.000 description 1
- TYERBRGKZKGLIN-UZTOHYMASA-N (6r)-6-(3-fluorophenyl)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-(3-hydroxypropyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=CC(F)=C1 TYERBRGKZKGLIN-UZTOHYMASA-N 0.000 description 1
- XYOSDNSXPKSGEX-UQBPGWFLSA-N (6r)-6-(3-hydroxypropyl)-6-phenyl-3-[(1s)-1-(4-thiophen-2-ylphenyl)ethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2SC=CC=2)=CC=CC=C1 XYOSDNSXPKSGEX-UQBPGWFLSA-N 0.000 description 1
- GIGKIWTUUYXUOR-YCRPNKLZSA-N (6r)-6-(4-fluorophenyl)-3-[(1s)-1-(2-fluorophenyl)ethyl]-6-(3-hydroxypropyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C(=CC=CC=2)F)=CC=C(F)C=C1 GIGKIWTUUYXUOR-YCRPNKLZSA-N 0.000 description 1
- KYOGYEPFKVIBHI-YCRPNKLZSA-N (6r)-6-(4-fluorophenyl)-3-[(1s)-1-(3-fluorophenyl)ethyl]-6-(3-hydroxypropyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=C(F)C=CC=2)=CC=C(F)C=C1 KYOGYEPFKVIBHI-YCRPNKLZSA-N 0.000 description 1
- YYVPBMMLVRUBCV-YCRPNKLZSA-N (6r)-6-(4-fluorophenyl)-3-[(1s)-1-(4-fluorophenyl)ethyl]-6-(3-hydroxypropyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(F)=CC=2)=CC=C(F)C=C1 YYVPBMMLVRUBCV-YCRPNKLZSA-N 0.000 description 1
- MKNKRKSYEVBGEW-UQBPGWFLSA-N (6r)-6-(4-fluorophenyl)-3-[(1s)-1-(4-morpholin-4-ylphenyl)ethyl]-6-prop-2-enyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CC=C)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)N2CCOCC2)=CC=C(F)C=C1 MKNKRKSYEVBGEW-UQBPGWFLSA-N 0.000 description 1
- JNVNRDZACWOLKL-XTEPFMGCSA-N (6r)-6-(4-fluorophenyl)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]propyl]-6-(3-hydroxypropyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](CC)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=C(F)C=C1 JNVNRDZACWOLKL-XTEPFMGCSA-N 0.000 description 1
- MNMFMEQQDAIIRC-RXFWQSSRSA-N (6r)-6-(4-fluorophenyl)-3-[(1s)-1-[4-(4-methylpiperazin-1-yl)phenyl]ethyl]-6-prop-2-enyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CC=C)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)N2CCN(C)CC2)=CC=C(F)C=C1 MNMFMEQQDAIIRC-RXFWQSSRSA-N 0.000 description 1
- QVGDKUIMKBFGRX-UPCLLVRISA-N (6r)-6-(4-fluorophenyl)-3-[(1s)-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]ethyl]-6-prop-2-enyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CC=C)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2SC(C)=NN=2)=CC=C(F)C=C1 QVGDKUIMKBFGRX-UPCLLVRISA-N 0.000 description 1
- FNTHZWPWNKYVAW-MGPUTAFESA-N (6r)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-3-[(1s)-1-phenylethyl]-1,3-oxazinan-2-one Chemical compound C1([C@]2(CCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC=CC=2)=CC=C(F)C=C1 FNTHZWPWNKYVAW-MGPUTAFESA-N 0.000 description 1
- DLIPKBDHTVAMKH-KSFYIVLOSA-N (6r)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-[(1s)-1-(4-methoxyphenyl)ethyl]-1,3-oxazinan-2-one Chemical compound C1=CC(OC)=CC=C1[C@H](C)N1C(=O)O[C@@](CCCO)(C=2C=CC(F)=CC=2)CC1 DLIPKBDHTVAMKH-KSFYIVLOSA-N 0.000 description 1
- XWZGVDFUDNIURY-AFMDSPMNSA-N (6r)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-[(1s)-1-(4-pyridin-3-ylphenyl)ethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=NC=CC=2)=CC=C(F)C=C1 XWZGVDFUDNIURY-AFMDSPMNSA-N 0.000 description 1
- WXCQUJIPBJWDOE-YCRPNKLZSA-N (6r)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-[(1s)-1-[3-(trifluoromethyl)phenyl]ethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=C(C=CC=2)C(F)(F)F)=CC=C(F)C=C1 WXCQUJIPBJWDOE-YCRPNKLZSA-N 0.000 description 1
- UJPQNTZWPPWTLB-CCLHPLFOSA-N (6r)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-[(1s)-1-[4-(2-methylpyridin-4-yl)phenyl]ethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=C(C)N=CC=2)=CC=C(F)C=C1 UJPQNTZWPPWTLB-CCLHPLFOSA-N 0.000 description 1
- XODWXICXBZWDEJ-YCRPNKLZSA-N (6r)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-[(1s)-1-[4-(trifluoromethyl)phenyl]ethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C(F)(F)F)=CC=C(F)C=C1 XODWXICXBZWDEJ-YCRPNKLZSA-N 0.000 description 1
- OUTTUYZQIHSHQF-LIRRHRJNSA-N (6r)-6-(4-fluorophenyl)-6-(hydroxymethyl)-3-[(1s)-1-phenylethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CO)CCN(C(O2)=O)[C@@H](C)C=2C=CC=CC=2)=CC=C(F)C=C1 OUTTUYZQIHSHQF-LIRRHRJNSA-N 0.000 description 1
- AYJUPGUNWJCYTA-BXKMTCNYSA-N (6r)-6-(4-fluorophenyl)-6-prop-2-enyl-3-[(1s)-1-[4-[3-(trifluoromethyl)pyrazol-1-yl]phenyl]ethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CC=C)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)N2N=C(C=C2)C(F)(F)F)=CC=C(F)C=C1 AYJUPGUNWJCYTA-BXKMTCNYSA-N 0.000 description 1
- YPCOLEPFZYAVIO-GOSISDBHSA-N (6r)-6-methyl-3-(3-methylphenyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound CC1=CC=CC(N2C(O[C@](C)(CC2)C=2C=CC=CC=2)=O)=C1 YPCOLEPFZYAVIO-GOSISDBHSA-N 0.000 description 1
- YXAJSFREPDODKP-JOCHJYFZSA-N (6r)-6-methyl-6-phenyl-3-(3-pyridin-3-ylphenyl)-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(C)C=2C=CC=CC=2)CN1C(C=1)=CC=CC=1C1=CC=CN=C1 YXAJSFREPDODKP-JOCHJYFZSA-N 0.000 description 1
- DSWZMJKPAYWMJP-OAQYLSRUSA-N (6r)-6-methyl-6-phenyl-3-(3-thiophen-2-ylphenyl)-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(C)C=2C=CC=CC=2)CN1C(C=1)=CC=CC=1C1=CC=CS1 DSWZMJKPAYWMJP-OAQYLSRUSA-N 0.000 description 1
- QZMQRSGOWWSPRH-SFHVURJKSA-N (6s)-3-(3-bromophenyl)-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(CCO)C=2C=CC=CC=2)CN1C1=CC=CC(Br)=C1 QZMQRSGOWWSPRH-SFHVURJKSA-N 0.000 description 1
- SLSMHOGJKAPYQU-QUGAMOGWSA-N (6s)-3-[(1r)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCO)CCN(C(O2)=O)[C@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=C(F)C=C1 SLSMHOGJKAPYQU-QUGAMOGWSA-N 0.000 description 1
- IXFAHRWELDAYLH-ONTIZHBOSA-N (6s)-3-[(1s)-1-(4-bromophenyl)propyl]-6-[(2s)-2,3-dihydroxypropyl]-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(C[C@H](O)CO)CCN(C(O2)=O)[C@@H](CC)C=2C=CC(Br)=CC=2)=CC=CC=C1 IXFAHRWELDAYLH-ONTIZHBOSA-N 0.000 description 1
- MBTNCMMQLDRCFF-SBUREZEXSA-N (6s)-3-[(1s)-1-[3-(2-hydroxy-2-methylpropoxy)phenyl]ethyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@]2(C)CCN(C(O2)=O)[C@@H](C)C=2C=C(OCC(C)(C)O)C=CC=2)=CC=CC=C1 MBTNCMMQLDRCFF-SBUREZEXSA-N 0.000 description 1
- GGACFHDUZMTPRC-UNPBGGOKSA-N (6s)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(2,3-dihydroxypropyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CC(O)CO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=C(F)C=C1 GGACFHDUZMTPRC-UNPBGGOKSA-N 0.000 description 1
- KZJJYBHEDRKZDJ-QYBDOPJKSA-N (6s)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=CC=C1 KZJJYBHEDRKZDJ-QYBDOPJKSA-N 0.000 description 1
- MJISMVNNZLUKIQ-HJPURHCSSA-N (6s)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(2-hydroxyethyl)-6-propan-2-yl-1,3-oxazinan-2-one Chemical compound O=C1O[C@](C(C)C)(CCO)CCN1[C@@H](C)C1=CC=C(C=2C(=CC(F)=CC=2)F)C=C1 MJISMVNNZLUKIQ-HJPURHCSSA-N 0.000 description 1
- PUCNQCMCYLVVQG-FYSMJZIKSA-N (6s)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(2-hydroxyethyl)-6-thiophen-2-yl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=CS1 PUCNQCMCYLVVQG-FYSMJZIKSA-N 0.000 description 1
- WDKUSULWDUIUML-MYUZEXMDSA-N (6s)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-6-(2-methylsulfonylethyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCS(C)(=O)=O)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=C(F)C=C1 WDKUSULWDUIUML-MYUZEXMDSA-N 0.000 description 1
- SFYBGGNXFRMOCN-VKGTZQKMSA-N (6s)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-6-[2-(2-hydroxyethoxy)ethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCOCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=C(F)C=C1 SFYBGGNXFRMOCN-VKGTZQKMSA-N 0.000 description 1
- GGACFHDUZMTPRC-IPZQTHRPSA-N (6s)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-[(2s)-2,3-dihydroxypropyl]-6-(4-fluorophenyl)-1,3-oxazinan-2-one Chemical compound C1([C@@]2(C[C@H](O)CO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C(=CC(F)=CC=2)F)=CC=C(F)C=C1 GGACFHDUZMTPRC-IPZQTHRPSA-N 0.000 description 1
- FREQEUPGLGPFPL-BATDWUPUSA-N (6s)-3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-[(2s)-2-hydroxypropyl]-6-phenyl-1,3-oxazinan-2-one Chemical compound C1=CC([C@H](C)N2CC[C@](OC2=O)(C[C@@H](O)C)C=2C=CC=CC=2)=CC=C1C1=CC=C(F)C=C1F FREQEUPGLGPFPL-BATDWUPUSA-N 0.000 description 1
- QBTXWKOWTNTLRJ-MMTVBGGISA-N (6s)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CC(C)(C)O)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=CC=C1 QBTXWKOWTNTLRJ-MMTVBGGISA-N 0.000 description 1
- IROTYPHWZUZEAY-SIBVEZHUSA-N (6s)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=CC=C1 IROTYPHWZUZEAY-SIBVEZHUSA-N 0.000 description 1
- MZYFOLDIGUNKJT-GQLBPIDVSA-N (6s)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-(2-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C1=CC([C@H](C)N2CC[C@](OC2=O)(CC(O)C)C=2C=CC=CC=2)=CC=C1C1=CC=C(F)C=C1 MZYFOLDIGUNKJT-GQLBPIDVSA-N 0.000 description 1
- KPROUAAIOYAJTP-BVZFJXPGSA-N (6s)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-(3-hydroxypropyl)-6-thiophen-2-yl-1,3-oxazinan-2-one Chemical compound C1([C@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=CS1 KPROUAAIOYAJTP-BVZFJXPGSA-N 0.000 description 1
- MZYFOLDIGUNKJT-JVAFGIKQSA-N (6s)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-[(2r)-2-hydroxypropyl]-6-phenyl-1,3-oxazinan-2-one Chemical compound C1=CC([C@H](C)N2CC[C@](OC2=O)(C[C@H](O)C)C=2C=CC=CC=2)=CC=C1C1=CC=C(F)C=C1 MZYFOLDIGUNKJT-JVAFGIKQSA-N 0.000 description 1
- MZYFOLDIGUNKJT-OSOCVKALSA-N (6s)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-[(2s)-2-hydroxypropyl]-6-phenyl-1,3-oxazinan-2-one Chemical compound C1=CC([C@H](C)N2CC[C@](OC2=O)(C[C@@H](O)C)C=2C=CC=CC=2)=CC=C1C1=CC=C(F)C=C1 MZYFOLDIGUNKJT-OSOCVKALSA-N 0.000 description 1
- IEQHZGFXUXYXTQ-DEOSSOPVSA-N (6s)-3-[3-(2,4-difluorophenyl)-4-fluorophenyl]-6-(2-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(CCO)C=2C(=CC=CC=2)F)CN1C(C=1)=CC=C(F)C=1C1=CC=C(F)C=C1F IEQHZGFXUXYXTQ-DEOSSOPVSA-N 0.000 description 1
- ARUZVQYBNVZOPN-DEOSSOPVSA-N (6s)-3-[3-(2-chloro-4-fluorophenyl)-4-fluorophenyl]-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(CCO)C=2C=CC=CC=2)CN1C(C=1)=CC=C(F)C=1C1=CC=C(F)C=C1Cl ARUZVQYBNVZOPN-DEOSSOPVSA-N 0.000 description 1
- WZELCWHHNLQSLR-QHCPKHFHSA-N (6s)-3-[5-chloro-6-(2,4-difluorophenyl)pyridin-2-yl]-6-(2-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(CCO)C=2C(=CC=CC=2)F)CN1C(N=1)=CC=C(Cl)C=1C1=CC=C(F)C=C1F WZELCWHHNLQSLR-QHCPKHFHSA-N 0.000 description 1
- OLBKTRLRMUXLGL-QHCPKHFHSA-N (6s)-3-[6-(2,4-difluorophenyl)pyridin-2-yl]-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(CCO)C=2C=CC=CC=2)CN1C(N=1)=CC=CC=1C1=CC=C(F)C=C1F OLBKTRLRMUXLGL-QHCPKHFHSA-N 0.000 description 1
- OFIMPNOQMXPORL-QHCPKHFHSA-N (6s)-3-[6-(2,4-difluorophenyl)pyridin-2-yl]-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(CCO)C=2C=CC(F)=CC=2)CN1C(N=1)=CC=CC=1C1=CC=C(F)C=C1F OFIMPNOQMXPORL-QHCPKHFHSA-N 0.000 description 1
- UCSYXQOCBXHUBZ-QHCPKHFHSA-N (6s)-3-[6-(2-chloro-4-fluorophenyl)pyridin-2-yl]-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(CCO)C=2C=CC=CC=2)CN1C(N=1)=CC=CC=1C1=CC=C(F)C=C1Cl UCSYXQOCBXHUBZ-QHCPKHFHSA-N 0.000 description 1
- XYMFJLWCTXMXHU-PPHZAIPVSA-N (6s)-6-(2-fluorophenyl)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-6-(3-hydroxypropyl)-1,3-oxazinan-2-one Chemical compound C1([C@]2(CCCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=CC=C1F XYMFJLWCTXMXHU-PPHZAIPVSA-N 0.000 description 1
- OUTJYNQORJHZGJ-QHCPKHFHSA-N (6s)-6-(2-fluorophenyl)-3-[6-(4-fluorophenyl)-1-oxidopyridin-1-ium-2-yl]-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical class C([C@](OC1=O)(CCO)C=2C(=CC=CC=2)F)CN1C([N+]=1[O-])=CC=CC=1C1=CC=C(F)C=C1 OUTJYNQORJHZGJ-QHCPKHFHSA-N 0.000 description 1
- RANVHNGWEKJNMD-QHCPKHFHSA-N (6s)-6-(4-fluorophenyl)-3-[6-(4-fluorophenyl)pyridin-2-yl]-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C([C@](OC1=O)(CCO)C=2C=CC(F)=CC=2)CN1C(N=1)=CC=CC=1C1=CC=C(F)C=C1 RANVHNGWEKJNMD-QHCPKHFHSA-N 0.000 description 1
- JYEWJDUADZPZCE-BTYIYWSLSA-N (6s)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-3-[(1s)-1-(4-methoxyphenyl)ethyl]-1,3-oxazinan-2-one Chemical compound C1=CC(OC)=CC=C1[C@H](C)N1C(=O)O[C@@](CCO)(C=2C=CC(F)=CC=2)CC1 JYEWJDUADZPZCE-BTYIYWSLSA-N 0.000 description 1
- ITPKJPZKIPYEII-BTYIYWSLSA-N (6s)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-3-[(1s)-1-(4-methylsulfonylphenyl)ethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)S(C)(=O)=O)=CC=C(F)C=C1 ITPKJPZKIPYEII-BTYIYWSLSA-N 0.000 description 1
- ZWTMCIUXORVJIZ-BVZFJXPGSA-N (6s)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-3-[(1s)-1-(4-pyridin-3-ylphenyl)ethyl]-1,3-oxazinan-2-one Chemical compound C1([C@@]2(CCO)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=NC=CC=2)=CC=C(F)C=C1 ZWTMCIUXORVJIZ-BVZFJXPGSA-N 0.000 description 1
- DLIPKBDHTVAMKH-AOMKIAJQSA-N (6s)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-[(1s)-1-(4-methoxyphenyl)ethyl]-1,3-oxazinan-2-one Chemical compound C1=CC(OC)=CC=C1[C@H](C)N1C(=O)O[C@](CCCO)(C=2C=CC(F)=CC=2)CC1 DLIPKBDHTVAMKH-AOMKIAJQSA-N 0.000 description 1
- WHFAYDWOCGWLNV-DFBJGRDBSA-N (6s)-6-methyl-3-[(1s)-1-[3-(2-oxo-2-piperazin-1-ylethoxy)phenyl]ethyl]-6-phenyl-1,3-oxazinan-2-one Chemical compound C1([C@]2(C)CCN(C(O2)=O)[C@@H](C)C=2C=C(OCC(=O)N3CCNCC3)C=CC=2)=CC=CC=C1 WHFAYDWOCGWLNV-DFBJGRDBSA-N 0.000 description 1
- XRTFMNIRZNJJHD-JXFKEZNVSA-N (6s)-6-methyl-6-(2-methylphenyl)-3-[(1s)-1-phenylethyl]-1,3-oxazinan-2-one Chemical compound C1([C@]2(C)CCN(C(O2)=O)[C@@H](C)C=2C=CC=CC=2)=CC=CC=C1C XRTFMNIRZNJJHD-JXFKEZNVSA-N 0.000 description 1
- QIMFMKBZKNFZQM-JXFKEZNVSA-N (6s)-6-methyl-6-(3-methylphenyl)-3-[(1s)-1-phenylethyl]-1,3-oxazinan-2-one Chemical compound C1([C@]2(C)CCN(C(O2)=O)[C@@H](C)C=2C=CC=CC=2)=CC=CC(C)=C1 QIMFMKBZKNFZQM-JXFKEZNVSA-N 0.000 description 1
- VQYBDAASFBMKEP-JXFKEZNVSA-N (6s)-6-methyl-6-(4-methylphenyl)-3-[(1s)-1-phenylethyl]-1,3-oxazinan-2-one Chemical compound C1([C@]2(C)CCN(C(O2)=O)[C@@H](C)C=2C=CC=CC=2)=CC=C(C)C=C1 VQYBDAASFBMKEP-JXFKEZNVSA-N 0.000 description 1
- QRRQCLQPRPKNCO-CYFREDJKSA-N (6s)-6-methyl-6-[4-(morpholin-4-ylmethyl)phenyl]-3-[(1s)-1-phenylethyl]-1,3-oxazinan-2-one Chemical compound C1=CC([C@]2(C)CCN(C(O2)=O)[C@@H](C)C=2C=CC=CC=2)=CC=C1CN1CCOCC1 QRRQCLQPRPKNCO-CYFREDJKSA-N 0.000 description 1
- 125000006536 (C1-C2)alkoxy group Chemical group 0.000 description 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 1
- ZTNCFXOBEGOOOT-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide;thiomorpholine Chemical compound C1CSCCN1.O=S1(=O)CCNCC1 ZTNCFXOBEGOOOT-UHFFFAOYSA-N 0.000 description 1
- WHFHUMNXSKTAOI-UHFFFAOYSA-N 1-(4-phenylphenyl)sulfonylpyrrolidine Chemical group C=1C=C(C=2C=CC=CC=2)C=CC=1S(=O)(=O)N1CCCC1 WHFHUMNXSKTAOI-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- HJCTZBGBBARVCG-UHFFFAOYSA-N 1-[2-[3-[1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl]ethyl]-3-ethylurea Chemical compound O=C1OC(CCNC(=O)NCC)(C=2C=CC(F)=CC=2)CCN1C(C)C(C=C1)=CC=C1C1=CC=C(F)C=C1F HJCTZBGBBARVCG-UHFFFAOYSA-N 0.000 description 1
- QDIAPKPZNBARDD-UHFFFAOYSA-N 1-[2-[3-[1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl]ethyl]-3-methylurea Chemical compound O=C1OC(CCNC(=O)NC)(C=2C=CC(F)=CC=2)CCN1C(C)C(C=C1)=CC=C1C1=CC=C(F)C=C1F QDIAPKPZNBARDD-UHFFFAOYSA-N 0.000 description 1
- RPFNAAPDFSAIEH-UHFFFAOYSA-N 1-[3-[3-[1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl]propyl]-3-methylurea Chemical compound O=C1OC(CCCNC(=O)NC)(C=2C=CC(F)=CC=2)CCN1C(C)C(C=C1)=CC=C1C1=CC=C(F)C=C1F RPFNAAPDFSAIEH-UHFFFAOYSA-N 0.000 description 1
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 description 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- FKKJWWOASDLEKD-XMMPIXPASA-N 2-[3-[(6r)-6-methyl-2-oxo-6-phenyl-1,3-oxazinan-3-yl]phenyl]benzonitrile Chemical compound C([C@](OC1=O)(C)C=2C=CC=CC=2)CN1C(C=1)=CC=CC=1C1=CC=CC=C1C#N FKKJWWOASDLEKD-XMMPIXPASA-N 0.000 description 1
- CYXMRZXZCHOSNT-UHFFFAOYSA-N 2-[3-[1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl]acetic acid Chemical compound C=1C=C(C=2C(=CC(F)=CC=2)F)C=CC=1C(C)N(C(O1)=O)CCC1(CC(O)=O)C1=CC=C(F)C=C1 CYXMRZXZCHOSNT-UHFFFAOYSA-N 0.000 description 1
- MBNRSVWNMXRAOH-UHFFFAOYSA-N 2-[3-[1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl]acetonitrile Chemical compound C=1C=C(C=2C(=CC(F)=CC=2)F)C=CC=1C(C)N(C(O1)=O)CCC1(CC#N)C1=CC=C(F)C=C1 MBNRSVWNMXRAOH-UHFFFAOYSA-N 0.000 description 1
- WTFZKLXGDXSJKV-UHFFFAOYSA-N 2-[3-[3-(2,4-difluorophenyl)phenyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]acetic acid Chemical compound O=C1OC(CC(=O)O)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=C(F)C=C1F WTFZKLXGDXSJKV-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- DBQPIDKKFFBXHS-UHFFFAOYSA-N 3-(3-chlorophenyl)-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C1=CC=CC(Cl)=C1 DBQPIDKKFFBXHS-UHFFFAOYSA-N 0.000 description 1
- ZOQDAVOCQCXTKU-UHFFFAOYSA-N 3-(4-chlorophenyl)-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C1=CC=C(Cl)C=C1 ZOQDAVOCQCXTKU-UHFFFAOYSA-N 0.000 description 1
- HZUSGVQSIVLCHY-UHFFFAOYSA-N 3-(4-fluorophenyl)-1,3-oxazinan-2-one Chemical compound C1=CC(F)=CC=C1N1C(=O)OCCC1 HZUSGVQSIVLCHY-UHFFFAOYSA-N 0.000 description 1
- PDLQGVHFCWEJBC-COYMHYPVSA-N 3-[(1s)-1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(2-hydroxypropyl)-6-propan-2-yl-1,3-oxazinan-2-one Chemical compound O=C1OC(CC(O)C)(C(C)C)CCN1[C@@H](C)C1=CC=C(C=2C(=CC(F)=CC=2)F)C=C1 PDLQGVHFCWEJBC-COYMHYPVSA-N 0.000 description 1
- NNLCNIPQMQIZLG-UHFFFAOYSA-N 3-[(3-bromophenyl)methyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1CC1=CC=CC(Br)=C1 NNLCNIPQMQIZLG-UHFFFAOYSA-N 0.000 description 1
- ILGOGSGLIHTTBQ-UHFFFAOYSA-N 3-[(4-bromophenyl)methyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1CC1=CC=C(Br)C=C1 ILGOGSGLIHTTBQ-UHFFFAOYSA-N 0.000 description 1
- IEUDNQIKLSMAIA-UZTOHYMASA-N 3-[(6r)-3-[(1s)-1-[4-(4-fluorophenyl)phenyl]ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanamide Chemical compound C1([C@@]2(CCC(N)=O)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)=CC=CC=C1 IEUDNQIKLSMAIA-UZTOHYMASA-N 0.000 description 1
- OYWVQGIBIKWLRC-HFJWLAOPSA-N 3-[(6r)-6-(4-fluorophenyl)-2-oxo-3-[(1s)-1-(4-pyridin-3-ylphenyl)ethyl]-1,3-oxazinan-6-yl]propanamide Chemical compound C1([C@@]2(CCC(N)=O)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C=2C=NC=CC=2)=CC=C(F)C=C1 OYWVQGIBIKWLRC-HFJWLAOPSA-N 0.000 description 1
- DPLXTCSBFGMWCF-UHFFFAOYSA-N 3-[1-(3-hydroxyphenyl)ethyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound C=1C=CC(O)=CC=1C(C)N(C(O1)=O)CCC1(C)C1=CC=CC=C1 DPLXTCSBFGMWCF-UHFFFAOYSA-N 0.000 description 1
- WOQTXQOMVPEQHH-UHFFFAOYSA-N 3-[1-(4-bromophenyl)ethyl]-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound C=1C=C(Br)C=CC=1C(C)N(C(O1)=O)CCC1(CCO)C1=CC=C(F)C=C1 WOQTXQOMVPEQHH-UHFFFAOYSA-N 0.000 description 1
- NOZAUIHWUFKYEA-UHFFFAOYSA-N 3-[1-(4-bromophenyl)ethyl]-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-1,3-oxazinan-2-one Chemical compound C=1C=C(Br)C=CC=1C(C)N(C(O1)=O)CCC1(CCCO)C1=CC=C(F)C=C1 NOZAUIHWUFKYEA-UHFFFAOYSA-N 0.000 description 1
- JQRPZOWAALFXBW-UHFFFAOYSA-N 3-[1-(4-bromophenyl)propyl]-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one Chemical compound BrC1=CC=C(C=C1)C(CC)N1C(OC(CC1)(CCO)C1=CC=C(C=C1)F)=O JQRPZOWAALFXBW-UHFFFAOYSA-N 0.000 description 1
- AGCSHHGFMAHUIK-UHFFFAOYSA-N 3-[1-(4-cyclopropylphenyl)ethyl]-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-1,3-oxazinan-2-one Chemical compound C=1C=C(C2CC2)C=CC=1C(C)N(C(O1)=O)CCC1(CCCO)C1=CC=C(F)C=C1 AGCSHHGFMAHUIK-UHFFFAOYSA-N 0.000 description 1
- GGACFHDUZMTPRC-UHFFFAOYSA-N 3-[1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(2,3-dihydroxypropyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one Chemical compound C=1C=C(C=2C(=CC(F)=CC=2)F)C=CC=1C(C)N(C(O1)=O)CCC1(CC(O)CO)C1=CC=C(F)C=C1 GGACFHDUZMTPRC-UHFFFAOYSA-N 0.000 description 1
- SHAJVFWHJXACEE-UHFFFAOYSA-N 3-[1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(2,3-dihydroxypropyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C=1C=C(C=2C(=CC(F)=CC=2)F)C=CC=1C(C)N(C(O1)=O)CCC1(CC(O)CO)C1=CC=CC=C1 SHAJVFWHJXACEE-UHFFFAOYSA-N 0.000 description 1
- FXZPUQXGCUIQCC-UHFFFAOYSA-N 3-[1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-[3-(dimethylamino)-2-hydroxypropyl]-6-(4-fluorophenyl)-1,3-oxazinan-2-one Chemical compound C=1C=C(C=2C(=CC(F)=CC=2)F)C=CC=1C(C)N(C(O1)=O)CCC1(CC(O)CN(C)C)C1=CC=C(F)C=C1 FXZPUQXGCUIQCC-UHFFFAOYSA-N 0.000 description 1
- AOHUCFUOVXHCLK-UHFFFAOYSA-N 3-[1-[4-(2-hydroxy-2-methylpropyl)phenyl]ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C=1C=C(CC(C)(C)O)C=CC=1C(C)N(C(O1)=O)CCC1(CCCO)C1=CC=CC=C1 AOHUCFUOVXHCLK-UHFFFAOYSA-N 0.000 description 1
- NTVSIYWAWYQYHA-UHFFFAOYSA-N 3-[1-[4-(5-acetylthiophen-2-yl)phenyl]ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C=1C=C(C=2SC(=CC=2)C(C)=O)C=CC=1C(C)N(C(O1)=O)CCC1(CCCO)C1=CC=CC=C1 NTVSIYWAWYQYHA-UHFFFAOYSA-N 0.000 description 1
- QAJYZVCUZHBDBT-UHFFFAOYSA-N 3-[1-[4-(5-fluoropyridin-3-yl)phenyl]ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound C=1C=C(C=2C=C(F)C=NC=2)C=CC=1C(C)N(C(O1)=O)CCC1(CCCO)C1=CC=CC=C1 QAJYZVCUZHBDBT-UHFFFAOYSA-N 0.000 description 1
- ADNJEURANCBRSE-UHFFFAOYSA-N 3-[2-(3-chlorophenyl)pyrimidin-4-yl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(N=1)=CC=NC=1C1=CC=CC(Cl)=C1 ADNJEURANCBRSE-UHFFFAOYSA-N 0.000 description 1
- DGRZIUAMDOMXOF-UHFFFAOYSA-N 3-[3-(4-hydroxyphenyl)phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=C(O)C=C1 DGRZIUAMDOMXOF-UHFFFAOYSA-N 0.000 description 1
- AZZYNBWIZLBWIJ-XMMPIXPASA-N 3-[3-[(6r)-6-methyl-2-oxo-6-phenyl-1,3-oxazinan-3-yl]phenyl]benzonitrile Chemical compound C([C@](OC1=O)(C)C=2C=CC=CC=2)CN1C(C=1)=CC=CC=1C1=CC=CC(C#N)=C1 AZZYNBWIZLBWIJ-XMMPIXPASA-N 0.000 description 1
- LMIMSEXLHFFLIQ-UHFFFAOYSA-N 3-[3-[1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl]propanoic acid Chemical compound C=1C=C(C=2C(=CC(F)=CC=2)F)C=CC=1C(C)N(C(O1)=O)CCC1(CCC(O)=O)C1=CC=C(F)C=C1 LMIMSEXLHFFLIQ-UHFFFAOYSA-N 0.000 description 1
- MSQIRKAOYTVRLM-UHFFFAOYSA-N 3-[3-[1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl]propylurea Chemical compound C=1C=C(C=2C(=CC(F)=CC=2)F)C=CC=1C(C)N(C(O1)=O)CCC1(CCCNC(N)=O)C1=CC=C(F)C=C1 MSQIRKAOYTVRLM-UHFFFAOYSA-N 0.000 description 1
- FNFJIBCRHWLYSA-UHFFFAOYSA-N 3-[3-[2-(hydroxymethyl)phenyl]phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=CC=C1CO FNFJIBCRHWLYSA-UHFFFAOYSA-N 0.000 description 1
- XADFXYXTYUJXAP-UHFFFAOYSA-N 3-[3-[3-(hydroxymethyl)phenyl]phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=CC(CO)=C1 XADFXYXTYUJXAP-UHFFFAOYSA-N 0.000 description 1
- HTUJSDTVPYYIOL-UHFFFAOYSA-N 3-[3-[4-(hydroxymethyl)phenyl]phenyl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=C(CO)C=C1 HTUJSDTVPYYIOL-UHFFFAOYSA-N 0.000 description 1
- AOWLBUQSIRIORC-UHFFFAOYSA-N 3-[4-(2,4-difluorophenyl)pyrimidin-2-yl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(N=1)=NC=CC=1C1=CC=C(F)C=C1F AOWLBUQSIRIORC-UHFFFAOYSA-N 0.000 description 1
- HJJUIMXFUNTMKM-UHFFFAOYSA-N 3-[4-(3-chlorophenyl)pyrimidin-2-yl]-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(N=1)=NC=CC=1C1=CC=CC(Cl)=C1 HJJUIMXFUNTMKM-UHFFFAOYSA-N 0.000 description 1
- PMPMRWISGCWLPG-UHFFFAOYSA-N 3-[6-(4-fluorophenyl)-1-oxidopyridin-1-ium-2-yl]-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(CCO)(C=2C=CC=CC=2)CCN1C([N+]=1[O-])=CC=CC=1C1=CC=C(F)C=C1 PMPMRWISGCWLPG-UHFFFAOYSA-N 0.000 description 1
- BGXUCYGAXBCMRB-UHFFFAOYSA-N 3-cyclohexyl-6-methyl-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C1CCCCC1 BGXUCYGAXBCMRB-UHFFFAOYSA-N 0.000 description 1
- XNLWJFYYOIRPIO-UHFFFAOYSA-N 3-phenylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1 XNLWJFYYOIRPIO-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- UMZCDOIEKIXFIV-OYHNWAKOSA-N 4-[(1s)-1-[(6r)-6-(4-fluorophenyl)-2-oxo-6-prop-2-enyl-1,3-oxazinan-3-yl]ethyl]benzamide Chemical compound C1([C@@]2(CC=C)CCN(C(O2)=O)[C@@H](C)C=2C=CC(=CC=2)C(N)=O)=CC=C(F)C=C1 UMZCDOIEKIXFIV-OYHNWAKOSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UGYHYQIDXZGMAX-UHFFFAOYSA-N 4-methylmorpholine;morpholine Chemical compound C1COCCN1.CN1CCOCC1 UGYHYQIDXZGMAX-UHFFFAOYSA-N 0.000 description 1
- LUQVCHRDAGWYMG-UHFFFAOYSA-N 4-phenylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=CC=C1 LUQVCHRDAGWYMG-UHFFFAOYSA-N 0.000 description 1
- NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VCPODQFWJPSLSA-UHFFFAOYSA-N 6-(2,3-dihydroxypropyl)-3-[1-(4-methoxyphenyl)ethyl]-6-phenyl-1,3-oxazinan-2-one Chemical compound C1=CC(OC)=CC=C1C(C)N1C(=O)OC(CC(O)CO)(C=2C=CC=CC=2)CC1 VCPODQFWJPSLSA-UHFFFAOYSA-N 0.000 description 1
- RRBGPJIVUHQVNA-UHFFFAOYSA-N 6-(2,3-dihydroxypropyl)-3-[1-[4-(4-fluorophenyl)phenyl]ethyl]-6-phenyl-1,3-oxazinan-2-one Chemical compound C=1C=C(C=2C=CC(F)=CC=2)C=CC=1C(C)N(C(O1)=O)CCC1(CC(O)CO)C1=CC=CC=C1 RRBGPJIVUHQVNA-UHFFFAOYSA-N 0.000 description 1
- GUQMIKJYVODPJS-UHFFFAOYSA-N 6-(2,3-dihydroxypropyl)-6-(4-fluorophenyl)-3-[1-(4-methoxyphenyl)ethyl]-1,3-oxazinan-2-one Chemical compound C1=CC(OC)=CC=C1C(C)N1C(=O)OC(CC(O)CO)(C=2C=CC(F)=CC=2)CC1 GUQMIKJYVODPJS-UHFFFAOYSA-N 0.000 description 1
- MFYAKLSNFATSPC-UHFFFAOYSA-N 6-(3-hydroxypropyl)-3-[1-[4-(methoxymethyl)phenyl]ethyl]-6-phenyl-1,3-oxazinan-2-one Chemical compound C1=CC(COC)=CC=C1C(C)N1C(=O)OC(CCCO)(C=2C=CC=CC=2)CC1 MFYAKLSNFATSPC-UHFFFAOYSA-N 0.000 description 1
- LTRXUVUZHLYZAT-UHFFFAOYSA-N 6-(3-hydroxypropyl)-6-phenyl-3-(2-phenylcyclopropyl)-1,3-oxazinan-2-one Chemical compound O=C1OC(CCCO)(C=2C=CC=CC=2)CCN1C1CC1C1=CC=CC=C1 LTRXUVUZHLYZAT-UHFFFAOYSA-N 0.000 description 1
- BBZWQERHKRLYJZ-UHFFFAOYSA-N 6-(3-hydroxypropyl)-6-phenyl-3-(2-phenylethyl)-1,3-oxazinan-2-one Chemical compound O=C1OC(CCCO)(C=2C=CC=CC=2)CCN1CCC1=CC=CC=C1 BBZWQERHKRLYJZ-UHFFFAOYSA-N 0.000 description 1
- MNLSSWJEOGCYBD-UHFFFAOYSA-N 6-(4-fluorophenyl)-3-[1-(2-fluorophenyl)ethyl]-6-(3-hydroxypropyl)-1,3-oxazinan-2-one;6-(4-fluorophenyl)-3-[1-(4-fluorophenyl)ethyl]-6-(3-hydroxypropyl)-1,3-oxazinan-2-one Chemical compound C=1C=C(F)C=CC=1C(C)N(C(O1)=O)CCC1(CCCO)C1=CC=C(F)C=C1.C=1C=CC=C(F)C=1C(C)N(C(O1)=O)CCC1(CCCO)C1=CC=C(F)C=C1 MNLSSWJEOGCYBD-UHFFFAOYSA-N 0.000 description 1
- CTRPZBRTYVJUCA-UHFFFAOYSA-N 6-(4-fluorophenyl)-3-[1-[4-(hydroxymethyl)phenyl]ethyl]-6-(3-hydroxypropyl)-1,3-oxazinan-2-one Chemical compound C=1C=C(CO)C=CC=1C(C)N(C(O1)=O)CCC1(CCCO)C1=CC=C(F)C=C1 CTRPZBRTYVJUCA-UHFFFAOYSA-N 0.000 description 1
- BGPQBTLALBOWIJ-UHFFFAOYSA-N 6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-[1-[4-(5-methoxypyridin-3-yl)phenyl]ethyl]-1,3-oxazinan-2-one Chemical compound COC1=CN=CC(C=2C=CC(=CC=2)C(C)N2C(OC(CCCO)(CC2)C=2C=CC(F)=CC=2)=O)=C1 BGPQBTLALBOWIJ-UHFFFAOYSA-N 0.000 description 1
- XODWXICXBZWDEJ-UHFFFAOYSA-N 6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-[1-[4-(trifluoromethyl)phenyl]ethyl]-1,3-oxazinan-2-one Chemical compound C=1C=C(C(F)(F)F)C=CC=1C(C)N(C(O1)=O)CCC1(CCCO)C1=CC=C(F)C=C1 XODWXICXBZWDEJ-UHFFFAOYSA-N 0.000 description 1
- ONULLFFDWJNXSD-UHFFFAOYSA-N 6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-[1-[4-[6-(trifluoromethyl)pyridin-3-yl]phenyl]ethyl]-1,3-oxazinan-2-one 6-(3-hydroxypropyl)-3-[1-(4-methoxyphenyl)ethyl]-6-phenyl-1,3-oxazinan-2-one Chemical compound OCCCC1(CCN(C(O1)=O)C(C)C1=CC=C(C=C1)OC)C1=CC=CC=C1.FC1=CC=C(C=C1)C1(CCN(C(O1)=O)C(C)C1=CC=C(C=C1)C=1C=NC(=CC1)C(F)(F)F)CCCO ONULLFFDWJNXSD-UHFFFAOYSA-N 0.000 description 1
- PONWBSMVJDWOFO-UHFFFAOYSA-N 6-methyl-3,6-diphenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C1=CC=CC=C1 PONWBSMVJDWOFO-UHFFFAOYSA-N 0.000 description 1
- BMBABFUGJFXFAJ-UHFFFAOYSA-N 6-methyl-3-[3-(2-methylsulfonylphenyl)phenyl]-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=CC=C1S(C)(=O)=O BMBABFUGJFXFAJ-UHFFFAOYSA-N 0.000 description 1
- HNOIWKRAJWIGSK-UHFFFAOYSA-N 6-methyl-3-[3-(3-methylsulfonylphenyl)phenyl]-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=CC(S(C)(=O)=O)=C1 HNOIWKRAJWIGSK-UHFFFAOYSA-N 0.000 description 1
- OUXBELOPSUAIAG-UHFFFAOYSA-N 6-methyl-3-[3-(4-methylsulfonylphenyl)phenyl]-6-phenyl-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=C(S(C)(=O)=O)C=C1 OUXBELOPSUAIAG-UHFFFAOYSA-N 0.000 description 1
- XRTFMNIRZNJJHD-UHFFFAOYSA-N 6-methyl-6-(2-methylphenyl)-3-(1-phenylethyl)-1,3-oxazinan-2-one Chemical compound C=1C=CC=CC=1C(C)N(C(O1)=O)CCC1(C)C1=CC=CC=C1C XRTFMNIRZNJJHD-UHFFFAOYSA-N 0.000 description 1
- QIMFMKBZKNFZQM-UHFFFAOYSA-N 6-methyl-6-(3-methylphenyl)-3-(1-phenylethyl)-1,3-oxazinan-2-one Chemical compound C=1C=CC=CC=1C(C)N(C(O1)=O)CCC1(C)C1=CC=CC(C)=C1 QIMFMKBZKNFZQM-UHFFFAOYSA-N 0.000 description 1
- VQYBDAASFBMKEP-UHFFFAOYSA-N 6-methyl-6-(4-methylphenyl)-3-(1-phenylethyl)-1,3-oxazinan-2-one Chemical compound C=1C=CC=CC=1C(C)N(C(O1)=O)CCC1(C)C1=CC=C(C)C=C1 VQYBDAASFBMKEP-UHFFFAOYSA-N 0.000 description 1
- XGJPEJODHXKZEZ-UHFFFAOYSA-N 6-methyl-6-(4-methylsulfanylphenyl)-3-(1-phenylethyl)-1,3-oxazinan-2-one Chemical compound C1=CC(SC)=CC=C1C1(C)OC(=O)N(C(C)C=2C=CC=CC=2)CC1 XGJPEJODHXKZEZ-UHFFFAOYSA-N 0.000 description 1
- LVYAAPIPLDIUSX-NYRJJRHWSA-N 6-methyl-6-phenyl-3-[(1r)-1-phenylethyl]-1,3-oxazinan-2-one Chemical compound O1C(=O)N([C@H](C)C=2C=CC=CC=2)CCC1(C)C1=CC=CC=C1 LVYAAPIPLDIUSX-NYRJJRHWSA-N 0.000 description 1
- XRCCLDNVURBCCJ-UHFFFAOYSA-N 6-methyl-6-phenyl-3-[3-[3-(2h-tetrazol-5-yl)phenyl]phenyl]-1,3-oxazinan-2-one Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C(C=1)=CC=CC=1C1=NN=NN1 XRCCLDNVURBCCJ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- ZMTHLTIHDFYKOP-UHFFFAOYSA-N BrC1=CC=C(C=C1)C(CC)N1C(OC(CC1)(C1=CC=CC=C1)CC(CO)O)=O.FC1=CC=C(C=C1)C1=CC=C(C=C1)C(C)N1C(OC(CC1)(C1=CC=CC=C1)CC(C)(C)O)=O Chemical compound BrC1=CC=C(C=C1)C(CC)N1C(OC(CC1)(C1=CC=CC=C1)CC(CO)O)=O.FC1=CC=C(C=C1)C1=CC=C(C=C1)C(C)N1C(OC(CC1)(C1=CC=CC=C1)CC(C)(C)O)=O ZMTHLTIHDFYKOP-UHFFFAOYSA-N 0.000 description 1
- TVNDLPFKSXPLBP-UKISQYQASA-N BrC1=CC=C(C=C1)[C@H](C)N1C(OC(CC1)(C(C)C)CCCO)=O.BrC1=CC=C(C=C1)[C@H](C)N1C(OC(CC1)(C(C)C)CCCO)=O Chemical compound BrC1=CC=C(C=C1)[C@H](C)N1C(OC(CC1)(C(C)C)CCCO)=O.BrC1=CC=C(C=C1)[C@H](C)N1C(OC(CC1)(C(C)C)CCCO)=O TVNDLPFKSXPLBP-UKISQYQASA-N 0.000 description 1
- JWPBDYQDDZIKQS-ONTIZHBOSA-N BrC1=CC=C(C=C1)[C@H](CC)N1C(O[C@](CC1)(C1=CC=C(C=C1)F)C[C@@H](CO)O)=O Chemical compound BrC1=CC=C(C=C1)[C@H](CC)N1C(O[C@](CC1)(C1=CC=C(C=C1)F)C[C@@H](CO)O)=O JWPBDYQDDZIKQS-ONTIZHBOSA-N 0.000 description 1
- JWPBDYQDDZIKQS-URVUXULASA-N BrC1=CC=C(C=C1)[C@H](CC)N1C(O[C@](CC1)(C1=CC=C(C=C1)F)C[C@H](CO)O)=O Chemical compound BrC1=CC=C(C=C1)[C@H](CC)N1C(O[C@](CC1)(C1=CC=C(C=C1)F)C[C@H](CO)O)=O JWPBDYQDDZIKQS-URVUXULASA-N 0.000 description 1
- DKNIDDLBGSDKKN-UHFFFAOYSA-N CC(N1CCC(CCN(C)C(C)=O)(OC1=O)c1ccc(F)cc1)c1ccc(cc1)-c1ccc(F)cc1F Chemical compound CC(N1CCC(CCN(C)C(C)=O)(OC1=O)c1ccc(F)cc1)c1ccc(cc1)-c1ccc(F)cc1F DKNIDDLBGSDKKN-UHFFFAOYSA-N 0.000 description 1
- COTOUBYYTMGCGA-UHFFFAOYSA-N CN(C)[S] Chemical group CN(C)[S] COTOUBYYTMGCGA-UHFFFAOYSA-N 0.000 description 1
- 101100451537 Caenorhabditis elegans hsd-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- SHPDMFSEXHSXKG-DEOSSOPVSA-N ClC1=C(C=CC(=C1)F)C1=CC(=CC=C1F)N1C(O[C@@](CC1)(CCO)C1=CC=C(C=C1)F)=O Chemical compound ClC1=C(C=CC(=C1)F)C1=CC(=CC=C1F)N1C(O[C@@](CC1)(CCO)C1=CC=C(C=C1)F)=O SHPDMFSEXHSXKG-DEOSSOPVSA-N 0.000 description 1
- IWDQXAQJBOXNQT-QHCPKHFHSA-N ClC1=C(C=CC(=C1)F)C1=CC=CC(=N1)N1C(O[C@@](CC1)(CCO)C1=CC=C(C=C1)F)=O Chemical compound ClC1=C(C=CC(=C1)F)C1=CC=CC(=N1)N1C(O[C@@](CC1)(CCO)C1=CC=C(C=C1)F)=O IWDQXAQJBOXNQT-QHCPKHFHSA-N 0.000 description 1
- ZORLACKLJKYOJW-QHCPKHFHSA-N ClC=1C=CC(=NC1C1=CC=C(C=C1)F)N1C(O[C@@](CC1)(CCO)C1=C(C=CC=C1)F)=O Chemical compound ClC=1C=CC(=NC1C1=CC=C(C=C1)F)N1C(O[C@@](CC1)(CCO)C1=C(C=CC=C1)F)=O ZORLACKLJKYOJW-QHCPKHFHSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 241001274613 Corvus frugilegus Species 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- TYQJYQYIJIVXSP-RUZDIDTESA-N FC1=C(C=CC(=C1)F)C1=CC(=CC=C1)N1C(O[C@](CC1)(C1=CC=CC=C1)CCCO)=O Chemical compound FC1=C(C=CC(=C1)F)C1=CC(=CC=C1)N1C(O[C@](CC1)(C1=CC=CC=C1)CCCO)=O TYQJYQYIJIVXSP-RUZDIDTESA-N 0.000 description 1
- VINFOQVRVMPOSN-OFVILXPXSA-N FC1=C(C=CC(=C1)F)C1=CC(=CC=C1)N1C(O[C@](CC1)(C1=CC=CC=C1)C[C@@H](CO)O)=O Chemical compound FC1=C(C=CC(=C1)F)C1=CC(=CC=C1)N1C(O[C@](CC1)(C1=CC=CC=C1)C[C@@H](CO)O)=O VINFOQVRVMPOSN-OFVILXPXSA-N 0.000 description 1
- PGSFCPKXIINFHZ-UHFFFAOYSA-N FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)C(C)N1C(OC(CC1)(C1=CC=C(C=C1)F)CCN(C)C)=O Chemical compound FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)C(C)N1C(OC(CC1)(C1=CC=C(C=C1)F)CCN(C)C)=O PGSFCPKXIINFHZ-UHFFFAOYSA-N 0.000 description 1
- OOAJXAPJXZEFRZ-UHFFFAOYSA-N FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)C(C)N1C(OC(CC1)(C1=CC=C(C=C1)F)CCNC(CO)=O)=O Chemical compound FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)C(C)N1C(OC(CC1)(C1=CC=C(C=C1)F)CCNC(CO)=O)=O OOAJXAPJXZEFRZ-UHFFFAOYSA-N 0.000 description 1
- BZWZSOSVQPFDKF-UHFFFAOYSA-N FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)C(C)N1C(OC(CC1)(CCC)C1=CC=CC=C1)=O.FC1=CC=C(C=C1)C1(CCN(C(O1)=O)C(C)C1=CC=C(C=C1)C=1C=NC=CC1)CCCO Chemical compound FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)C(C)N1C(OC(CC1)(CCC)C1=CC=CC=C1)=O.FC1=CC=C(C=C1)C1(CCN(C(O1)=O)C(C)C1=CC=C(C=C1)C=1C=NC=CC1)CCCO BZWZSOSVQPFDKF-UHFFFAOYSA-N 0.000 description 1
- SNDUQSURYVCBQD-UHMYUZELSA-N FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)[C@H](C)N1C(O[C@@](CC1)(C[C@@H](C)O)C1=CC=C(C=C1)F)=O Chemical compound FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)[C@H](C)N1C(O[C@@](CC1)(C[C@@H](C)O)C1=CC=C(C=C1)F)=O SNDUQSURYVCBQD-UHMYUZELSA-N 0.000 description 1
- SNDUQSURYVCBQD-VFUKXHBFSA-N FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)[C@H](C)N1C(O[C@@](CC1)(C[C@H](C)O)C1=CC=C(C=C1)F)=O Chemical compound FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)[C@H](C)N1C(O[C@@](CC1)(C[C@H](C)O)C1=CC=C(C=C1)F)=O SNDUQSURYVCBQD-VFUKXHBFSA-N 0.000 description 1
- GGACFHDUZMTPRC-MUDFHLJKSA-N FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)[C@H](C)N1C(O[C@](CC1)(C1=CC=C(C=C1)F)C[C@H](CO)O)=O Chemical compound FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)[C@H](C)N1C(O[C@](CC1)(C1=CC=C(C=C1)F)C[C@H](CO)O)=O GGACFHDUZMTPRC-MUDFHLJKSA-N 0.000 description 1
- FREQEUPGLGPFPL-RYTUXRKISA-N FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)[C@H](C)N1C(O[C@](CC1)(C1=CC=CC=C1)C[C@@H](C)O)=O Chemical compound FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)[C@H](C)N1C(O[C@](CC1)(C1=CC=CC=C1)C[C@@H](C)O)=O FREQEUPGLGPFPL-RYTUXRKISA-N 0.000 description 1
- SHAJVFWHJXACEE-CAASOKRLSA-N FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)[C@H](C)N1C(O[C@](CC1)(C1=CC=CC=C1)C[C@@H](CO)O)=O Chemical compound FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)[C@H](C)N1C(O[C@](CC1)(C1=CC=CC=C1)C[C@@H](CO)O)=O SHAJVFWHJXACEE-CAASOKRLSA-N 0.000 description 1
- SHAJVFWHJXACEE-ZPBOBRSPSA-N FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)[C@H](C)N1C(O[C@](CC1)(C1=CC=CC=C1)C[C@H](CO)O)=O Chemical compound FC1=C(C=CC(=C1)F)C1=CC=C(C=C1)[C@H](C)N1C(O[C@](CC1)(C1=CC=CC=C1)C[C@H](CO)O)=O SHAJVFWHJXACEE-ZPBOBRSPSA-N 0.000 description 1
- URQVFDCWQACMSU-DEOSSOPVSA-N FC1=CC=C(C=C1)[C@]1(CCN(C(O1)=O)C=1C=C(C(=CC1)F)C1=C(C=C(C=C1)F)F)CCO Chemical compound FC1=CC=C(C=C1)[C@]1(CCN(C(O1)=O)C=1C=C(C(=CC1)F)C1=C(C=C(C=C1)F)F)CCO URQVFDCWQACMSU-DEOSSOPVSA-N 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 101000928753 Homo sapiens 11-beta-hydroxysteroid dehydrogenase 1 Proteins 0.000 description 1
- 101100499217 Homo sapiens HSD11B1 gene Proteins 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- CRCDKDMVWUJKOK-UHFFFAOYSA-N NC=1N(C=CN=1)CCC1(CCN(C(O1)=O)C(C)C1=CC=C(C=C1)C1=C(C=C(C=C1)F)F)C1=CC=C(C=C1)F Chemical compound NC=1N(C=CN=1)CCC1(CCN(C(O1)=O)C(C)C1=CC=C(C=C1)C1=C(C=C(C=C1)F)F)C1=CC=C(C=C1)F CRCDKDMVWUJKOK-UHFFFAOYSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- XFUGUEMBKDCQEY-UHFFFAOYSA-N OCCC1=CC=C(C=C1)C(C)N1C(OC(CC1)(C1=CC=CC=C1)CCCO)=O.C1(CCCCC1)C(C)N1C(OC(CC1)(C1=CC=C(C=C1)F)CC(CO)O)=O Chemical compound OCCC1=CC=C(C=C1)C(C)N1C(OC(CC1)(C1=CC=CC=C1)CCCO)=O.C1(CCCCC1)C(C)N1C(OC(CC1)(C1=CC=C(C=C1)F)CC(CO)O)=O XFUGUEMBKDCQEY-UHFFFAOYSA-N 0.000 description 1
- YUNHJSMQKKBINU-QHCPKHFHSA-N OCC[C@@]1(CCN(C(=O)O1)c1cccc(n1)-c1ccc(F)cc1Cl)c1ccccc1F Chemical compound OCC[C@@]1(CCN(C(=O)O1)c1cccc(n1)-c1ccc(F)cc1Cl)c1ccccc1F YUNHJSMQKKBINU-QHCPKHFHSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000013521 Visual disease Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- OBZHEBDUNPOCJG-SZTGPWMUSA-N carbenoxolone Chemical compound C([C@H]1C2=CC(=O)[C@@H]34)[C@](C)(C(O)=O)CC[C@@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@H]1[C@@]3(C)CC[C@@H](OC(=O)CCC(O)=O)C1(C)C OBZHEBDUNPOCJG-SZTGPWMUSA-N 0.000 description 1
- 229960000530 carbenoxolone Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 150000001886 cortisols Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000008846 dynamic interplay Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000001288 lysyl group Chemical group 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- PUSRESMCCNQIKR-UHFFFAOYSA-N methyl 4-[1-[6-(4-fluorophenyl)-6-(3-hydroxypropyl)-2-oxo-1,3-oxazinan-3-yl]ethyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C(C)N1C(=O)OC(CCCO)(C=2C=CC(F)=CC=2)CC1 PUSRESMCCNQIKR-UHFFFAOYSA-N 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- BRXUGSOLBGZIFK-UHFFFAOYSA-N n-[2-[3-[1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl]ethyl]acetamide Chemical compound C=1C=C(C=2C(=CC(F)=CC=2)F)C=CC=1C(C)N(C(O1)=O)CCC1(CCNC(C)=O)C1=CC=C(F)C=C1 BRXUGSOLBGZIFK-UHFFFAOYSA-N 0.000 description 1
- RGMQKUNJMKQDMC-UHFFFAOYSA-N n-[2-[3-[1-[4-(2,4-difluorophenyl)phenyl]ethyl]-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl]ethyl]methanesulfonamide Chemical compound C=1C=C(C=2C(=CC(F)=CC=2)F)C=CC=1C(C)N(C(O1)=O)CCC1(CCNS(C)(=O)=O)C1=CC=C(F)C=C1 RGMQKUNJMKQDMC-UHFFFAOYSA-N 0.000 description 1
- PKWVHEPXDSCDST-UHFFFAOYSA-N n-[3-[3-(1-cyclohexylethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl]propyl]methanesulfonamide Chemical compound C1CC(CCCNS(C)(=O)=O)(C=2C=CC(F)=CC=2)OC(=O)N1C(C)C1CCCCC1 PKWVHEPXDSCDST-UHFFFAOYSA-N 0.000 description 1
- BQCXLHLPSDTZNI-UHFFFAOYSA-N n-[3-[3-[1-[4-(4-fluorophenyl)phenyl]ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propyl]methanesulfonamide Chemical compound C=1C=C(C=2C=CC(F)=CC=2)C=CC=1C(C)N(C(O1)=O)CCC1(CCCNS(C)(=O)=O)C1=CC=CC=C1 BQCXLHLPSDTZNI-UHFFFAOYSA-N 0.000 description 1
- PSPIQDPGFCXATC-UHFFFAOYSA-N n-[4-[1-[6-(4-fluorophenyl)-6-(2-hydroxyethyl)-2-oxo-1,3-oxazinan-3-yl]ethyl]phenyl]methanesulfonamide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1C(C)N(C(O1)=O)CCC1(CCO)C1=CC=C(F)C=C1 PSPIQDPGFCXATC-UHFFFAOYSA-N 0.000 description 1
- QKCJMVJSSQRSAV-UHFFFAOYSA-N n-[[3-[3-(6-methyl-2-oxo-6-phenyl-1,3-oxazinan-3-yl)phenyl]phenyl]methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC(C=2C=C(C=CC=2)N2C(OC(C)(CC2)C=2C=CC=CC=2)=O)=C1 QKCJMVJSSQRSAV-UHFFFAOYSA-N 0.000 description 1
- HEDFYCNIBLVIDC-UHFFFAOYSA-N n-[[4-[3-(6-methyl-2-oxo-6-phenyl-1,3-oxazinan-3-yl)phenyl]phenyl]methyl]methanesulfonamide Chemical compound O=C1OC(C)(C=2C=CC=CC=2)CCN1C(C=1)=CC=CC=1C1=CC=C(CNS(C)(=O)=O)C=C1 HEDFYCNIBLVIDC-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- ICLPSGCMAXCYLJ-UHFFFAOYSA-N tert-butyl 3-[6-(3-hydroxypropyl)-2-oxo-6-phenyl-1,3-oxazinan-3-yl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1N1C(=O)OC(CCCO)(C=2C=CC=CC=2)CC1 ICLPSGCMAXCYLJ-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96205807P | 2007-07-26 | 2007-07-26 | |
| US60/962,058 | 2007-07-26 | ||
| US125307P | 2007-10-31 | 2007-10-31 | |
| US61/001,253 | 2007-10-31 | ||
| US4965008P | 2008-05-01 | 2008-05-01 | |
| US61/049,650 | 2008-05-01 | ||
| PCT/US2008/009017 WO2009017664A1 (en) | 2007-07-26 | 2008-07-25 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010534654A JP2010534654A (ja) | 2010-11-11 |
| JP2010534654A5 JP2010534654A5 (enExample) | 2013-06-13 |
| JP5451611B2 true JP5451611B2 (ja) | 2014-03-26 |
Family
ID=39942701
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518226A Expired - Fee Related JP5451611B2 (ja) | 2007-07-26 | 2008-07-25 | 11β−ヒドロキシステロイドデヒドロゲナーゼ1のサイクリックインヒビター |
| JP2010518233A Expired - Fee Related JP5470557B2 (ja) | 2007-07-26 | 2008-07-25 | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型の阻害剤の合成 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518233A Expired - Fee Related JP5470557B2 (ja) | 2007-07-26 | 2008-07-25 | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型の阻害剤の合成 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8575156B2 (enExample) |
| EP (2) | EP2183229B1 (enExample) |
| JP (2) | JP5451611B2 (enExample) |
| AR (1) | AR067673A1 (enExample) |
| AT (1) | ATE554078T1 (enExample) |
| CA (2) | CA2697147A1 (enExample) |
| CL (1) | CL2008002199A1 (enExample) |
| ES (1) | ES2395081T3 (enExample) |
| TW (1) | TW200911796A (enExample) |
| WO (2) | WO2009017671A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014015475A (ja) * | 2008-07-25 | 2014-01-30 | Boehringer Ingelheim Internatl Gmbh | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2125750B1 (en) | 2007-02-26 | 2014-05-21 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| WO2009017671A1 (en) | 2007-07-26 | 2009-02-05 | Vitae Pharmaceuticals, Inc. | Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| AR069207A1 (es) | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
| EP2220048B1 (en) * | 2007-11-16 | 2017-01-25 | Boehringer Ingelheim International GmbH | Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use |
| US8440658B2 (en) | 2007-12-11 | 2013-05-14 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| TW200934490A (en) | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
| US8592409B2 (en) | 2008-01-24 | 2013-11-26 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| JP5734666B2 (ja) * | 2008-02-11 | 2015-06-17 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の1,3−オキサアゼパン−2−オン及び1,3−ジアゼパン−2−オン阻害剤 |
| EP2245014B1 (en) * | 2008-02-12 | 2011-11-02 | Boehringer Ingelheim International GmbH | Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use |
| CA2715290A1 (en) | 2008-02-15 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| WO2009117109A1 (en) * | 2008-03-18 | 2009-09-24 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| CA2723034A1 (en) * | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2291373B1 (en) * | 2008-05-01 | 2013-09-11 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2291371B1 (en) * | 2008-05-01 | 2015-06-10 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| JP5301563B2 (ja) * | 2008-05-01 | 2013-09-25 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター |
| EP2288596B1 (en) | 2008-05-13 | 2016-11-30 | Boehringer Ingelheim International GmbH | Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use |
| ES2526966T3 (es) | 2008-06-05 | 2015-01-19 | Glaxo Group Limited | Compuestos novedosos |
| ES2445199T3 (es) | 2008-06-05 | 2014-02-28 | Glaxo Group Limited | Derivados de benzpirazol como inhibidores de PI3-quinasas |
| ATE552255T1 (de) | 2008-06-05 | 2012-04-15 | Glaxo Group Ltd | 4-aminoindazole |
| WO2010010150A1 (en) * | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| CA2729998A1 (en) * | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| WO2010046445A2 (en) | 2008-10-23 | 2010-04-29 | Boehringer Ingelheim International Gmbh | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use |
| JP5679997B2 (ja) * | 2009-02-04 | 2015-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤 |
| WO2010102958A1 (en) | 2009-03-09 | 2010-09-16 | Glaxo Group Limited | 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases |
| AP2011005948A0 (en) * | 2009-04-30 | 2011-10-31 | Boehringer Ingelheim Int | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1. |
| MA33216B1 (fr) | 2009-04-30 | 2012-04-02 | Boehringer Ingelheim Int | Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1 |
| CA2759476C (en) | 2009-04-30 | 2018-10-09 | Julie Nicole Hamblin | Novel compounds |
| AR076492A1 (es) * | 2009-04-30 | 2011-06-15 | Boehringer Ingelheim Int | Inhibidores ciclicos de 11 beta -hidroxiesteroide deshidrogenasa 1 |
| WO2010139673A1 (en) * | 2009-06-02 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| WO2011011123A1 (en) * | 2009-06-11 | 2011-01-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
| EP2448928B1 (en) | 2009-07-01 | 2014-08-13 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| WO2011056737A1 (en) | 2009-11-05 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Novel chiral phosphorus ligands |
| UY33001A (es) | 2009-11-06 | 2011-05-31 | Boehringer Ingelheim Int | Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| JP2013531636A (ja) | 2010-05-26 | 2013-08-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 2−オキソ−1,2−ジヒドロピリジン−4−イルボロン酸誘導体 |
| US8933072B2 (en) | 2010-06-16 | 2015-01-13 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| EP2585444B1 (en) * | 2010-06-25 | 2014-10-22 | Boehringer Ingelheim International GmbH | Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| WO2012059416A1 (en) | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
| TWI537258B (zh) | 2010-11-05 | 2016-06-11 | 百靈佳殷格翰國際股份有限公司 | 六氫茚并吡啶及八氫苯并喹啉之芳基-及雜環芳基羰基衍生物 |
| JP2014508125A (ja) * | 2010-12-20 | 2014-04-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジアステレオ異性有機化合物の製造方法 |
| EP2744783A1 (en) | 2011-08-17 | 2014-06-25 | Boehringer Ingelheim International GmbH | Indenopyridine derivatives |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9234054B2 (en) * | 2011-12-19 | 2016-01-12 | Saudi Basic Industries Corporation | Process for the preparation of metallocene complexes |
| CN104080792A (zh) * | 2011-12-19 | 2014-10-01 | 沙特基础工业公司 | 用于制备茂金属络合物的方法 |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| SG11201700777VA (en) | 2014-08-04 | 2017-02-27 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| SG11201808003RA (en) | 2016-04-15 | 2018-10-30 | Abbvie Inc | Bromodomain inhibitors |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
| TWI872177B (zh) | 2019-12-20 | 2025-02-11 | 丹麥商紐韋盧森公司 | 對核受體具有活性之化合物 |
| US11447479B2 (en) | 2019-12-20 | 2022-09-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
| CA3174176A1 (en) | 2020-03-31 | 2021-10-07 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
| JP7713953B2 (ja) | 2020-03-31 | 2025-07-28 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
Family Cites Families (211)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3378587A (en) | 1963-03-14 | 1968-04-16 | Du Pont | 3, 3'-diaminomethyl-1, 1'-biadamantane |
| NL127995C (enExample) | 1963-12-20 | Geigy Ag J R | ||
| US3341538A (en) | 1965-06-18 | 1967-09-12 | Geigy Chem Corp | Certain 2, 6-methano-3-benzazocines |
| DE2108954A1 (en) | 1971-02-25 | 1972-09-07 | Boehringer Sohn Ingelheim | 2-(furylmethyl)-6,7-benzomorphans - useful as cns active agents |
| DE1801556A1 (de) | 1968-10-05 | 1970-05-21 | Huels Chemische Werke Ag | Verfahren zur Herstellung von substituierten Hexahydropyrimidinonen-(2) |
| GB1304175A (enExample) | 1969-03-31 | 1973-01-24 | ||
| DE2105743C3 (de) | 1971-02-08 | 1979-11-29 | Boehringer Sohn Ingelheim | 2-(Furylmethyl)- a -5,9-dialkyl -6,7benzomorphane, Verfahren zu ihrer Herstellung und deren Verwendung |
| US3681349A (en) | 1970-03-05 | 1972-08-01 | Morton Norwich Products Inc | 1-(substituted benzyl) tetrahydro-2-(1h) pyrimidones |
| US4043927A (en) | 1972-03-07 | 1977-08-23 | Sun Ventures, Inc. | Friction or tractive drive containing ethers of adamantanes |
| DE2229695A1 (de) | 1972-06-19 | 1974-01-31 | Boehringer Sohn Ingelheim | 2-(heteroaryl-methyl)-5,9 beta-dialkyl6,7-benzomorphane, deren saeureadditionssalze sowie verfahren zu deren herstellung |
| DE2338369A1 (de) | 1973-07-26 | 1975-02-13 | Schering Ag | Mikrobiologische hydroxylierung von 2,6-methano-3-benzazocinen |
| SU511005A3 (ru) | 1973-10-27 | 1976-04-15 | К.Х.Берингер Зон., (Фирма) | Способ получени (метоксиметилфурилметил)6,7-бензоморфанов или морфинанов |
| US4009171A (en) | 1974-02-21 | 1977-02-22 | Sterling Drug Inc. | N-acylated-11-oxygenated-2,6-methano-3-benzazocine intermediates |
| DE2411382C3 (de) | 1974-03-09 | 1979-09-06 | C.H. Boehringer Sohn, 6507 Ingelheim | 2-Tetrahydrofurfuryl-6,7-benzomorphane, Verfahren zur Herstellung und deren Verwendung |
| US4136145A (en) | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
| US4136162A (en) | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
| DE2437610A1 (de) | 1974-08-05 | 1976-02-26 | Boehringer Sohn Ingelheim | Neue 5,9-beta-disubstituierte 2-tetrahydrofurfuryl-6,7-benzomorphane, deren saeureadditionssalze, ihre verwendung als arzneimittel und verfahren zu deren herstellung |
| GB1513961A (en) | 1975-02-25 | 1978-06-14 | Acf Chemiefarma Nv | 6,7-benzomorphans method for their preparation and intermediates |
| US4108857A (en) | 1975-08-18 | 1978-08-22 | Sterling Drug Inc. | Imidazolylmethyl methanobenzazocines |
| DE2828039A1 (de) | 1978-06-26 | 1980-01-10 | Boehringer Sohn Ingelheim | 2-(2-alkoxyethyl)-2'-hydroxy-6,7-benzomorphane deren saeureadditionssalze diese enthaltende arzneimittel und verfahren zu deren herstellung |
| US5393735A (en) | 1990-08-09 | 1995-02-28 | Rohm And Haas Company | Herbicidal glutarimides |
| CA2023492A1 (en) | 1989-08-31 | 1991-03-01 | Barry Clifford Lange | Herbicidal glutarimides |
| US5098916A (en) | 1990-03-29 | 1992-03-24 | G. D. Searle & Co. | Propanobicyclic amine derivatives for cns disorders |
| EP0454444A1 (en) | 1990-04-24 | 1991-10-30 | Nissan Chemical Industries Ltd. | Glutarimide derivatives and herbicides |
| US5215992A (en) | 1990-04-30 | 1993-06-01 | G. D. Searle & Co. | Ethanobicyclic amine derivatives for CNS disorders |
| US5089506A (en) | 1990-04-30 | 1992-02-18 | G. D. Searle & Co. | Ethanobicyclic amine derivatives for cns disorders |
| CA2049244A1 (en) | 1990-08-16 | 1992-02-17 | Steven H. Christiansen | Process for absorption of sulfur compounds from fluids using heterocyclic compounds having at least one ring nitrogen atom |
| WO1992006971A1 (en) | 1990-10-10 | 1992-04-30 | Schering Corporation | Pyridine and pyridine n-oxide derivatives of diaryl methyl piperidines or piperazines, and compositions and methods of use thereof |
| DE4119611A1 (de) * | 1991-06-14 | 1992-12-17 | Bayer Ag | Mittel zur bekaempfung von schaedlingen auf basis substituierter oxazolidinone, neue substituierte oxazolidinone, deren herstellung und verwendung |
| US5610294A (en) | 1991-10-11 | 1997-03-11 | The Du Pont Merck Pharmaceutical Company | Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors |
| CA2112129C (en) | 1992-04-30 | 1997-10-07 | Shingo Yano | Oxazolidine derivative and pharmaceutically acceptable salt thereof |
| JPH0753721B2 (ja) | 1992-09-11 | 1995-06-07 | 工業技術院長 | 環状ウレタン化合物の製造法 |
| GB9225377D0 (en) | 1992-12-04 | 1993-01-27 | Ici Plc | Herbicides |
| AU668818B2 (en) | 1993-04-07 | 1996-05-16 | Taiho Pharmaceutical Co., Ltd. | Thiazolidine derivative and pharmaceutical composition containing the same |
| TW280812B (enExample) | 1993-07-02 | 1996-07-11 | Bayer Ag | |
| EP0640594A1 (en) | 1993-08-23 | 1995-03-01 | Fujirebio Inc. | Hydantoin derivative as metalloprotease inhibitor |
| JPH07157681A (ja) | 1993-12-08 | 1995-06-20 | Konica Corp | 有機顔料の製造方法及び有機顔料を含有する電子写真感光体 |
| JPH07309850A (ja) * | 1994-05-16 | 1995-11-28 | Canon Inc | 光学活性化合物、それを含有する液晶組成物、それを有する液晶素子及びそれらを用いた表示方法、表示装置 |
| DE19500118A1 (de) | 1994-05-18 | 1995-11-23 | Bayer Ag | Substituierte Diazacyclohexandi(thi)one |
| FR2729954B1 (fr) | 1995-01-30 | 1997-08-01 | Sanofi Sa | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US5780466A (en) | 1995-01-30 | 1998-07-14 | Sanofi | Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present |
| GB9510459D0 (en) | 1995-05-24 | 1995-07-19 | Zeneca Ltd | Bicyclic amines |
| US5776959A (en) | 1995-06-05 | 1998-07-07 | Washington University | Anticonvulsant and anxiolytic lactam and thiolactam derivatives |
| GB9517622D0 (en) | 1995-08-29 | 1995-11-01 | Univ Edinburgh | Regulation of intracellular glucocorticoid concentrations |
| JPH09151179A (ja) | 1995-11-30 | 1997-06-10 | Canon Inc | 光学活性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた液晶装置及び表示方法 |
| US6251897B1 (en) | 1996-07-31 | 2001-06-26 | Nikken Chemicals Co., Ltd | 6-phenyltetrahydro-1,3-oxazin-2-one derivative and pharmaceutical composition containing the same |
| US5866702A (en) | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
| US6794390B2 (en) | 1996-08-02 | 2004-09-21 | Cv Therapeutics, Inc. | Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha |
| GB9623944D0 (en) | 1996-11-15 | 1997-01-08 | Zeneca Ltd | Bicyclic amine derivatives |
| US6159990A (en) | 1997-06-18 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Oxazolidinones as α1A receptor antagonists |
| US6089506A (en) * | 1997-06-30 | 2000-07-18 | Scheffel; Bernd W. | Thermal center flight indicator for gliders |
| TR200001199T2 (tr) * | 1997-11-07 | 2000-08-21 | Pharmacia & Upjohn Company | Oksazolidinonların üretimi için işlem |
| US5936124A (en) | 1998-06-22 | 1999-08-10 | Sepacor Inc. | Fluoxetine process from benzoylpropionic acid |
| US7410995B1 (en) | 1998-08-14 | 2008-08-12 | Gpi Nil Holdings Inc. | N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders |
| DE19918725A1 (de) | 1999-04-24 | 2000-10-26 | Bayer Ag | Substituierte N-Cyano-sulfonsäureanilide |
| DE19929348A1 (de) | 1999-06-26 | 2000-12-28 | Bayer Ag | Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten |
| US7256005B2 (en) | 1999-08-10 | 2007-08-14 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity |
| CA2381111A1 (en) | 1999-08-26 | 2001-03-01 | Leah M. Giupponi | Npy antagonists: spiroisoquinolinone derivatives |
| EP1237874B1 (en) | 1999-12-17 | 2006-02-22 | Schering Corporation | Selective neurokinin antagonists |
| US6436928B1 (en) | 1999-12-17 | 2002-08-20 | Schering Corporation | Selective neurokinin antagonists |
| GB0003397D0 (en) | 2000-02-14 | 2000-04-05 | Merck Sharp & Dohme | Therapeutic agents |
| DE10034623A1 (de) | 2000-07-17 | 2002-01-31 | Bayer Ag | Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren |
| DE10034800A1 (de) | 2000-07-18 | 2002-01-31 | Bayer Ag | Substituierte Benzostickstoffheterocyclen |
| DE10034803A1 (de) | 2000-07-18 | 2002-01-31 | Bayer Ag | Substituierte Sulfonsäureanilide |
| DE10035928A1 (de) | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
| DE10035908A1 (de) | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
| DE10035927A1 (de) | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
| ATE307127T1 (de) | 2000-08-16 | 2005-11-15 | Neurogen Corp | 2,4-substituierte pyridinderivate |
| US7294637B2 (en) | 2000-09-11 | 2007-11-13 | Sepracor, Inc. | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter |
| WO2002022572A2 (en) | 2000-09-11 | 2002-03-21 | Sepracor, Inc. | Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| JP2002179572A (ja) | 2000-10-06 | 2002-06-26 | Nikken Chem Co Ltd | アレルギー性眼疾患治療剤 |
| US6841671B2 (en) | 2000-10-26 | 2005-01-11 | Pfizer Inc. | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| US20030143668A1 (en) | 2001-06-18 | 2003-07-31 | National Institute Of Advanced Industrial | Guanosine triphosphate-binding protein coupled receptors |
| JP3873115B2 (ja) | 2001-09-25 | 2007-01-24 | 独立行政法人産業技術総合研究所 | 環状ウレタン製造方法 |
| JP4545437B2 (ja) | 2001-10-15 | 2010-09-15 | シェーリング コーポレイション | アデノシンa2a受容体アンタゴニストとしてのイミダゾ(4,3−e)−1,2,4−トリアゾロ(1,5−c)ピリミジン |
| RU2004118719A (ru) | 2001-11-22 | 2005-03-27 | Оно Фармасьютикал Ко., Лтд. (Jp) | Производные пиперидин-2-она и фармацевтические композиции, содержащие такие соединения в качестве активного ингредиента |
| JP2003300884A (ja) | 2002-04-08 | 2003-10-21 | Nikken Chem Co Ltd | TNF−α産生阻害剤 |
| CA2483075A1 (en) | 2002-04-26 | 2003-11-06 | Pfizer Products Inc. | Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
| EP1501833B1 (en) | 2002-04-26 | 2005-11-02 | Pfizer Products Inc. | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| ES2357057T3 (es) | 2002-04-30 | 2011-04-15 | Kudos Pharmaceuticals Limited | Derivados de ftalazinona. |
| MXPA04011327A (es) | 2002-05-17 | 2005-08-15 | Jenken Biosciences Inc | Opioides y compuestos similares a opioides y usos de los mismos. |
| ATE358482T1 (de) | 2002-07-03 | 2007-04-15 | Schering Corp | 1-amido-4-phenyl-4-benzyloxymethyl-piperidin derivative und verwandte verbindungen als neurokinin-1 (nk-1) antagonsisten zur behandlung von erbrechen, depressionen, angstzustände und husten |
| WO2004009559A2 (en) | 2002-07-18 | 2004-01-29 | Queen's University At Kingston | Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents |
| GB0218630D0 (en) | 2002-08-10 | 2002-09-18 | Tanabe Seiyaku Co | Novel compounds |
| TWI347946B (en) | 2002-10-11 | 2011-09-01 | Otsuka Pharma Co Ltd | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound |
| WO2004046137A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| GB0228410D0 (en) | 2002-12-05 | 2003-01-08 | Glaxo Group Ltd | Novel Compounds |
| US7208487B2 (en) | 2002-12-13 | 2007-04-24 | Cytokinetics, Incorporated | Compounds, compositions and methods |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| US7276520B2 (en) | 2003-03-26 | 2007-10-02 | Merck & Co., Inc. | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists |
| US7700583B2 (en) | 2003-04-11 | 2010-04-20 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
| JP4629657B2 (ja) | 2003-04-11 | 2011-02-09 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型化活性化合物 |
| DE10358004A1 (de) | 2003-12-11 | 2005-07-14 | Abbott Gmbh & Co. Kg | Ketolactam-Verbindungen und ihre Verwendung |
| US7186844B2 (en) | 2004-01-13 | 2007-03-06 | Mitsubishi Gas Chemical Co., Inc. | Method for producing cyclic carbamate ester |
| JP4324669B2 (ja) | 2004-01-21 | 2009-09-02 | 独立行政法人産業技術総合研究所 | 環状ウレタンの製造方法 |
| JP2005239670A (ja) | 2004-02-27 | 2005-09-08 | Ono Pharmaceut Co Ltd | 含窒素複素環化合物およびその医薬用途 |
| US7619086B2 (en) | 2004-03-09 | 2009-11-17 | Merck & Co., Inc. | HIV integrase inhibitors |
| US8519158B2 (en) | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| JP2005272321A (ja) | 2004-03-23 | 2005-10-06 | Ono Pharmaceut Co Ltd | 含窒素複素環化合物およびその医薬用途 |
| MXPA06012932A (es) | 2004-05-07 | 2007-01-26 | Janssen Pharmaceutica Nv | Derivados de pirrolidin-2-ona y piperidin-2-ona como inhibidores de 11-beta hidroxiesteroide deshidrogenasa. |
| GB0411404D0 (en) | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
| AU2005247929B2 (en) | 2004-05-24 | 2010-03-11 | Amgen Inc. | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| JP2008504278A (ja) | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | アミド化合物およびその医薬としての使用 |
| GB0414438D0 (en) | 2004-06-28 | 2004-07-28 | Syngenta Participations Ag | Chemical compounds |
| DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| EP1621536A1 (en) | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| EP1621535A1 (en) | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| EP1621539A1 (en) | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| WO2006017443A2 (en) | 2004-08-02 | 2006-02-16 | Osi Pharmaceuticals, Inc. | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
| US7544677B2 (en) | 2004-08-23 | 2009-06-09 | Merck & Co., Inc. | Inhibitors of Akt activity |
| JP5208505B2 (ja) * | 2004-08-30 | 2013-06-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 11−ベータヒドロキシステロイドデヒドロゲナーゼ阻害剤としてのn−2アダマンタニル−2−フェノキシ−アセトアミド誘導体 |
| EP1791821B1 (en) | 2004-09-10 | 2013-06-05 | Janssen Pharmaceutica NV | Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms) |
| CN102731499B (zh) | 2004-11-10 | 2016-01-13 | 因塞特控股公司 | 内酰胺化合物及其作为药物的应用 |
| US20060167044A1 (en) | 2004-12-20 | 2006-07-27 | Arnaiz Damian O | Piperidine derivatives and their use as anti-inflammatory agents |
| EP1828163A2 (en) | 2004-12-23 | 2007-09-05 | CHIESI FARMACEUTICI S.p.A. | Azole derivatives with antimuscarinic activity |
| WO2006071819A1 (en) | 2004-12-28 | 2006-07-06 | Exelixis, Inc. | [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| CN101107245A (zh) | 2005-01-19 | 2008-01-16 | 神经能质公司 | 经杂芳基取代的哌嗪-吡啶类似物 |
| PE20061093A1 (es) | 2005-02-16 | 2006-11-10 | Schering Corp | Piperazinas sustituidas con heterociclos con actividad antagonista de cxcr3 |
| CN101213185A (zh) | 2005-02-16 | 2008-07-02 | 先灵公司 | 具有cxcr3拮抗活性的吡啶基和苯基取代的哌嗪-哌啶 |
| CA2598458A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| JP2008530212A (ja) | 2005-02-16 | 2008-08-07 | シェーリング コーポレイション | Cxcr3アンタゴニスト活性を有するピペラジン−ピペリジン |
| CN101146793A (zh) | 2005-02-16 | 2008-03-19 | 先灵公司 | 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物 |
| MX2007009948A (es) | 2005-02-16 | 2007-09-26 | Schering Corp | Pierazin-piperidinas sustituidas con piridilo y fenilo conectados por aminos con actividad antagonista de cxcr3. |
| WO2006090792A1 (ja) | 2005-02-24 | 2006-08-31 | Nihon Nohyaku Co., Ltd. | 新規なハロアルキルスルホンアニリド誘導体、除草剤及びその使用方法 |
| US20090264650A1 (en) | 2005-03-31 | 2009-10-22 | Nobuo Cho | Prophylactic/Therapeutic Agent for Diabetes |
| CN104109156A (zh) | 2005-04-12 | 2014-10-22 | 维科尔药物公司 | 新颖的三环血管紧张素ii激动剂 |
| WO2007008529A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc | Celullar cholesterol absorption modifiers |
| WO2007017510A2 (de) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Isophthalsäurediamide zur behandlung der alzheimer erkrankung |
| EP1924265A4 (en) | 2005-08-16 | 2010-06-02 | Genzyme Corp | COMPOUNDS BINDING TO CHEMOKINE RECEPTORS |
| EP1937666B1 (en) | 2005-10-11 | 2012-02-22 | Schering Corporation | Substituted heterocyclic compounds with cxcr3 antagonist activity |
| WO2007048595A1 (en) | 2005-10-27 | 2007-05-03 | Ucb Pharma, S.A. | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses |
| JP2007140188A (ja) | 2005-11-18 | 2007-06-07 | Fujifilm Corp | ポジ型感光性組成物及びそれを用いたパターン形成方法 |
| WO2007061661A2 (en) | 2005-11-22 | 2007-05-31 | Amgen Inc. | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| KR101415861B1 (ko) | 2005-12-05 | 2014-07-04 | 인사이트 코포레이션 | 락탐 화합물 및 이를 사용하는 방법 |
| EP1801098A1 (en) | 2005-12-16 | 2007-06-27 | Merck Sante | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors |
| WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| DE102005062990A1 (de) | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln |
| WO2007081569A2 (en) | 2005-12-30 | 2007-07-19 | Merck & Co., Inc. | Cetp inhibitors |
| CA2635262C (en) | 2005-12-30 | 2011-08-16 | Merck & Co., Inc. | 1, 3-oxazolidin-2-one derivatives useful as cetp inhibitors |
| WO2007081570A2 (en) * | 2005-12-30 | 2007-07-19 | Merck & Co., Inc. | Cholesteryl ester transfer protein inhibitors |
| WO2007081571A2 (en) | 2005-12-30 | 2007-07-19 | Merck & Co., Inc. | Cetp inhibitors |
| US7998959B2 (en) | 2006-01-12 | 2011-08-16 | Incyte Corporation | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| RU2455925C2 (ru) | 2006-02-27 | 2012-07-20 | БАЙЕР ХЕЛТКЭА ЭлЭлСи | Определение исследуемого вещества с поправкой на температуру для систем биодатчиков |
| TW200808807A (en) | 2006-03-02 | 2008-02-16 | Incyte Corp | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| US20070208001A1 (en) | 2006-03-03 | 2007-09-06 | Jincong Zhuo | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| WO2007109456A2 (en) | 2006-03-16 | 2007-09-27 | Pharmacopeia, Inc. | Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists |
| JP2007254409A (ja) | 2006-03-24 | 2007-10-04 | Taisho Pharmaceut Co Ltd | イミダゾリジノン誘導体 |
| US7435833B2 (en) | 2006-04-07 | 2008-10-14 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| CN101426769A (zh) | 2006-04-20 | 2009-05-06 | 杜邦公司 | 五元杂环无脊椎害虫防治剂 |
| WO2007124337A1 (en) | 2006-04-21 | 2007-11-01 | Eli Lilly And Company | Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1 |
| JP5236628B2 (ja) * | 2006-04-21 | 2013-07-17 | イーライ リリー アンド カンパニー | 11−β−ヒドロキシステロイドデヒドロゲナーゼ1阻害剤としての、シクロヘキシルイミダゾールラクタム誘導体 |
| US7968585B2 (en) | 2006-04-25 | 2011-06-28 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| US8178005B2 (en) | 2006-06-20 | 2012-05-15 | Chemtura Corporation | Liquid phosphite compositions having different alkyl groups |
| PE20080344A1 (es) | 2006-06-27 | 2008-06-09 | Sanofi Aventis | Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1 |
| WO2008012622A2 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| WO2008012623A1 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| US7538107B2 (en) | 2006-08-15 | 2009-05-26 | Wyeth | Oxazinan-2-one derivatives useful as PR modulators |
| US7649007B2 (en) | 2006-08-15 | 2010-01-19 | Wyeth Llc | Oxazolidine derivatives as PR modulators |
| US7618989B2 (en) | 2006-08-15 | 2009-11-17 | Wyeth | Tricyclic oxazolidone derivatives useful as PR modulators |
| CA2661503A1 (en) | 2006-08-25 | 2008-02-28 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11.beta. -hydroxysteroid dehydrogenase type 1 |
| EP2061780A4 (en) | 2006-09-14 | 2010-12-22 | Zalicus Pharmaceuticals Ltd | DIARYLE PIPERIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS |
| BRPI0718509A2 (pt) | 2006-09-22 | 2015-09-29 | Novartis Ag | compostos orgânicos heterocíclicos |
| DE102007005799B4 (de) | 2006-10-18 | 2018-01-25 | Heinz-Jürgen Mühlen | Verfahren zur Erzeugung eines wasserstoffreichen Produktgases |
| TW200829171A (en) | 2006-11-17 | 2008-07-16 | Nihon Nohyaku Co Ltd | Haloalkyl sulfonanilide derivatives or salts thereof, herbicide using it as effective constituent and use-method thereof |
| EP1935420A1 (en) | 2006-12-21 | 2008-06-25 | Merck Sante | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors |
| EP2125750B1 (en) | 2007-02-26 | 2014-05-21 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| JP2010522174A (ja) | 2007-03-23 | 2010-07-01 | シェーリング コーポレイション | Hcvns3−プロテアーゼ阻害剤としてのヒドラジド−ペプチド |
| WO2008119663A1 (en) | 2007-03-29 | 2008-10-09 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| WO2009017671A1 (en) | 2007-07-26 | 2009-02-05 | Vitae Pharmaceuticals, Inc. | Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| WO2009020140A1 (ja) | 2007-08-06 | 2009-02-12 | Dainippon Sumitomo Pharma Co., Ltd. | アダマンチルウレア誘導体 |
| JP2009110842A (ja) | 2007-10-31 | 2009-05-21 | Sumitomo Chemical Co Ltd | ボタンスイッチ被覆用積層樹脂体 |
| AR069207A1 (es) | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
| EP2220048B1 (en) | 2007-11-16 | 2017-01-25 | Boehringer Ingelheim International GmbH | Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use |
| US8440658B2 (en) | 2007-12-11 | 2013-05-14 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| KR101460359B1 (ko) | 2007-12-13 | 2014-11-10 | 삼성전자주식회사 | 이동통신 시스템에서의 핸드오버 방법 및 장치 |
| TW200934490A (en) | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
| US8592409B2 (en) | 2008-01-24 | 2013-11-26 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| JP5734666B2 (ja) | 2008-02-11 | 2015-06-17 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の1,3−オキサアゼパン−2−オン及び1,3−ジアゼパン−2−オン阻害剤 |
| EP2245014B1 (en) | 2008-02-12 | 2011-11-02 | Boehringer Ingelheim International GmbH | Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use |
| CA2715290A1 (en) | 2008-02-15 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| US8383629B2 (en) | 2008-02-27 | 2013-02-26 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 |
| JP5108557B2 (ja) | 2008-02-27 | 2012-12-26 | 東京エレクトロン株式会社 | ロードロック装置および基板冷却方法 |
| WO2009117109A1 (en) | 2008-03-18 | 2009-09-24 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| TW200944526A (en) | 2008-04-22 | 2009-11-01 | Vitae Pharmaceuticals Inc | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| CA2723034A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| JP5301563B2 (ja) | 2008-05-01 | 2013-09-25 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター |
| EP2291373B1 (en) | 2008-05-01 | 2013-09-11 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2291371B1 (en) | 2008-05-01 | 2015-06-10 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2288596B1 (en) | 2008-05-13 | 2016-11-30 | Boehringer Ingelheim International GmbH | Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use |
| US20110224242A1 (en) | 2008-07-23 | 2011-09-15 | Bioalliance Pharma | Styrlyquinolines, their process of preparation and their therapeutic uses |
| WO2010010174A1 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | 1,1'-diadamantyl carboxylic acids, medicaments containing such compounds and their use |
| WO2010010150A1 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| PL2324018T3 (pl) | 2008-07-25 | 2014-02-28 | Boehringer Ingelheim Int | Cykliczne inhibitory dehydrogenazy 11 beta-hydroksysteroidowej typu 1 |
| CA2729998A1 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| US8609690B2 (en) | 2008-08-25 | 2013-12-17 | Boehringer Ingelheim International Gmbh | Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use |
| WO2010046445A2 (en) | 2008-10-23 | 2010-04-29 | Boehringer Ingelheim International Gmbh | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use |
| CA2750517A1 (en) | 2009-02-04 | 2010-08-12 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| JP5679997B2 (ja) | 2009-02-04 | 2015-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤 |
| EP2405913A1 (en) | 2009-03-09 | 2012-01-18 | Bristol-Myers Squibb Company | Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists |
| MA33216B1 (fr) | 2009-04-30 | 2012-04-02 | Boehringer Ingelheim Int | Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1 |
| KR20120061771A (ko) | 2009-04-30 | 2012-06-13 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
| AR076936A1 (es) | 2009-06-02 | 2011-07-20 | Vitae Pharmaceuticals Inc | Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1 |
| WO2010139673A1 (en) | 2009-06-02 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| WO2011011123A1 (en) | 2009-06-11 | 2011-01-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
| EP2448928B1 (en) | 2009-07-01 | 2014-08-13 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2475652A1 (en) | 2009-09-11 | 2012-07-18 | Cylene Pharmaceuticals, Inc. | Pharmaceutically useful heterocycle-substituted lactams |
| WO2011056737A1 (en) | 2009-11-05 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Novel chiral phosphorus ligands |
| UY33001A (es) | 2009-11-06 | 2011-05-31 | Boehringer Ingelheim Int | Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina |
| US8933072B2 (en) | 2010-06-16 | 2015-01-13 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| EP2585444B1 (en) | 2010-06-25 | 2014-10-22 | Boehringer Ingelheim International GmbH | Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders |
| WO2012059416A1 (en) | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
-
2008
- 2008-07-25 WO PCT/US2008/009048 patent/WO2009017671A1/en not_active Ceased
- 2008-07-25 US US12/670,205 patent/US8575156B2/en not_active Expired - Fee Related
- 2008-07-25 EP EP08794755A patent/EP2183229B1/en not_active Not-in-force
- 2008-07-25 JP JP2010518226A patent/JP5451611B2/ja not_active Expired - Fee Related
- 2008-07-25 EP EP08794727.1A patent/EP2183228B1/en not_active Not-in-force
- 2008-07-25 CA CA2697147A patent/CA2697147A1/en not_active Abandoned
- 2008-07-25 AT AT08794755T patent/ATE554078T1/de active
- 2008-07-25 US US12/670,209 patent/US8329897B2/en not_active Expired - Fee Related
- 2008-07-25 TW TW097128296A patent/TW200911796A/zh unknown
- 2008-07-25 JP JP2010518233A patent/JP5470557B2/ja not_active Expired - Fee Related
- 2008-07-25 WO PCT/US2008/009017 patent/WO2009017664A1/en not_active Ceased
- 2008-07-25 CL CL2008002199A patent/CL2008002199A1/es unknown
- 2008-07-25 ES ES08794755T patent/ES2395081T3/es active Active
- 2008-07-25 CA CA2697168A patent/CA2697168A1/en not_active Abandoned
- 2008-07-25 AR ARP080103215A patent/AR067673A1/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014015475A (ja) * | 2008-07-25 | 2014-01-30 | Boehringer Ingelheim Internatl Gmbh | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター |
Also Published As
| Publication number | Publication date |
|---|---|
| TW200911796A (en) | 2009-03-16 |
| AR067673A1 (es) | 2009-10-21 |
| JP2010534656A (ja) | 2010-11-11 |
| EP2183228A1 (en) | 2010-05-12 |
| US20100256363A1 (en) | 2010-10-07 |
| EP2183229B1 (en) | 2012-04-18 |
| JP2010534654A (ja) | 2010-11-11 |
| WO2009017671A1 (en) | 2009-02-05 |
| US20110015157A1 (en) | 2011-01-20 |
| EP2183228B1 (en) | 2014-08-20 |
| US8329897B2 (en) | 2012-12-11 |
| CA2697147A1 (en) | 2009-02-05 |
| ATE554078T1 (de) | 2012-05-15 |
| JP5470557B2 (ja) | 2014-04-16 |
| WO2009017664A1 (en) | 2009-02-05 |
| CL2008002199A1 (es) | 2009-10-23 |
| US8575156B2 (en) | 2013-11-05 |
| CA2697168A1 (en) | 2009-02-05 |
| ES2395081T3 (es) | 2013-02-08 |
| EP2183229A1 (en) | 2010-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5451611B2 (ja) | 11β−ヒドロキシステロイドデヒドロゲナーゼ1のサイクリックインヒビター | |
| JP5696037B2 (ja) | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター | |
| JP5538365B2 (ja) | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤 | |
| ES2432150T3 (es) | Inhibidores cíclicos de la 11 beta-hidroxiesteroide deshidrogenasa 1 | |
| JP5451752B2 (ja) | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター | |
| JP5679997B2 (ja) | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤 | |
| JP5752181B2 (ja) | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター | |
| JP5777030B2 (ja) | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の阻害剤 | |
| EP2220052B1 (en) | CYCLIC UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | |
| US8680281B2 (en) | Lactam inhibitors of 11-β-hydroxysteroid dehydrogenase 1 | |
| US20120108579A1 (en) | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | |
| JP5784006B2 (ja) | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110713 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110713 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120702 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130325 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20130412 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130416 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130417 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130801 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130806 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131105 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131203 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131226 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |